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 Breast cancer is one of the most common and fatal cancer diseases that affect 
women worldwide. As is true with most other cancer diseases, early detection of breast 
cancer is very crucial for proper medical treatment because treatment of advanced breast 
cancer will be much more difficult and inconsistent. Screening and testing of breast 
cancer biomarkers, either genetic or proteomic, are among techniques used for diagnosis 
of breast cancers. Nevertheless, none of the biomarkers is by itself sensitive and selective 
enough for diagnosis of breast cancer, and thus, multi-analyte assays towards detection of 
multiple breast cancer biomarkers from different classes are desired for accurate 
diagnosis of this disease. 
 Described is a methodology with which both genetic and protein biomarkers of 
breast cancers are detected simultaneously on the same platform. This methodology 
consists of a novel hybrid biosensor system in a universal Zipcode DNA array format on 
the platform of polymer-based microfluidic devices. Detection of the genetic mutated 
material and the protein targeting material is through hybridization events between the 
arrayed universal Zipcode DNA sequences and the corresponding complementary 
Zipcode DNA sequences that are incorporated into both biomarkers during materials 
preparation. Signal generation and detection are through near-IR, laser-induced 
fluorescence imaging method. The hybrid biosensor system combines the strengths of 
microfluidic devices—high throughput, low sample consumption, and high kinetics—
with that of the universal DNA array format, which uncouples detection from 
hybridization event, thereby increasing the sensitivity of detection. Near-IR laser-induced 
fluorescence detection method adds further sensitivity to this system. 
 xviii
 In this work, surface properties of the microfluidic device substrate, PMMA have 
been manipulated in surface functionalities, surface topography, and surface wettabilities. 
Biomolecules including both antibodies and DNA have been successfully immobilized 
onto the UV-modified PMMA surfaces. The targeting biomarker materials were prepared 
using distinct protocols: PCR/LDR combined assays were adopted to prepare the breast 
cancer gene marker BRCA1 mutated material, while the protein antigen CEA targeting 
complex was achieved by a semi-synthetic method. Monitoring and characterization of 
surface manipulation, bio-functionalization, and targeting materials preparation were 
accomplished by unique analytical tools. 
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CHAPTER 1.  INTRODUCTION 
1.1  RESEARCH MOTIVATION, GOALS, AND SYNOPSIS  
  Breast cancer still imposes a significant health burden on women worldwide. As 
is true with most other cancer diseases, early diagnosis and implementation of prompt 
treatment are crucial in battling this disease. Biological markers from blood, urine, and 
tissue can signal predisposition, onset, response to drug treatment, and recurrence of 
breast cancer. Thus discovery and early detection of biomarkers are among the 
techniques that play significant roles in early diagnosis, effective prognosis, and close 
monitoring in treatment of breast cancers.  
There are several major classes of biomarkers for each specific type of cancer: 
mutations (changes) in genetic materials, usually deoxyribonucleic acid (DNA, Figure 
1.1 and 1.2) including small-scale mutation such as deletion, insertion, point mutation or 
exchange of a single nucleotide for another and large-scale mutations such as 
amplifications, deletions, formation of fusion genes, and loss of heterozygosity—DNA 
mutation. Over/under expression of gene activity reflected by mutations in messenger 
RNA (DNA → mRNA → protein), and the presence of functional proteins secreted in 
serum or on circulating tumor cells (protein biomarkers).1 Unfortunately, none of the 
biomarkers monitored to date are present in sufficient abundance to allow them to be 
sensitively and selectively detected using diagnostic assays such that they can act as sole 
prognostic of the disease. Thus it is highly desirable to test for the presence of multiple 
biomarkers in tandem so as to generate and interrogate information on one specific type 
of cancer.2 Moreover, different classes of biomarkers need to be evaluated in order to 
provide significant molecular profiling information for clinical practice in cancer 
diseases.1 Therefore, novel and sensitive technologies capable of simultaneous detection 
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Figure 1.1 Composition and structure of DNA. Top-bases composing DNA: Adenine, 
Guanine, Cytosine, and Thymine (Uracil is found in RNA). Bottom-schematic of the 
double-stranded DNA which is held together by hydrogen bonding between the base 
pairs Adenine and Thymine, and Guanine and Cytosine. Each strand is comprised of 












Overall, the project described here focuses on development of a methodology for 
early diagnosis of breast cancer using simultaneous detection of biomarkers via a 
microfluidic device platform. This methodology is intended to combine the strengths of 
microfluidics ― high throughput, low sample consumption, and low detection limit ― 
with the highly parallel characteristics of the microarray technologies and the high 
sensitivity/low limit of detection near-IR fluorescence techniques. By achieving this 
methodology, it is to make multianalyte (multiple biomarkers originating from the same 
disease) detection will be a reality and, the accuracy of diagnosis will be improved by 
reductions in the false negative and false positive outcomes.   
 In brief, the goal is a hybrid biosensor system fabricated on a polymer-based 
microfluidic device that utilize a unique format ― Zipcode universal DNA arrays that 
will direct each capture probe (genetic and protein capture probes for a given breast 
cancer biomarker) to a specific locus on the polymer device surface ― that decouples the 














Figure 1.2 Chemical structure of a deoxyribonucleotide (nucleotide) composed of a 




hybridization event from the detection event, and thereby improves the accuracy of the 
technique. Here, the genetic biomarker (gene mutational sequence) that is named breast 
cancer type I gene, or BRCA1, will be prepared through a polymerase chain reaction 
(PCR)/ligase detection reaction (LDR) coupled assay using genomic DNA isolated from 
a breast cancer cell line as the template; the protein biomarker (cell surface over-
expressed protein) will be semi-synthesized by cross-linking the anti-protein biomarker 
antibody with the cZipcode oligonucleotide (oligo) DNA sequence. Signal generation 
and transduction are achieved through near-IR fluorescence detection which minimizes 
background fluorescence interference and therefore increase the sensitivity of detection.  
The specifics of the methodology are outlined in Figure 1.3, and have its heart the 
use of short, single-stranded DNA sequences (24mers, named “Zipcode oligos”) arrayed 
on PMMA microfluidic device surfaces. The genetic biomarker targeting material 
cZip11-BRCA1 consists of a mutated base (the red star in the sequence), a 24-mer 
sequence that is complementary to the Zipcode11 oligo DNA sequence or cZipcode11 
sequence (the short piece of DNA sequence in orange color) on one end and a near-IR 
dye on the other end. The protein biomarker capture probe, for example, is a conjugate of 
the anti-human carcinoembryonic antigen (CEA) antibody with the cZipcode1 sequence 
(sequence in blue color). This antibody-oligo DNA conjugate will react with a specific 
antigen (the protein biomarker-red heart shape) and a detection antibody (labeled with a 
near-IR fluorescent dye) to form a sandwich immunoassay complex, or a protein 
biomarker targeting material. Finally, both genetic and protein biomarker targeting 
materials will be introduced to the arrayed Zipcode oligo DNA surfaces, and the 
















   
1.2  GENERAL INFORMATION ON CANCER DISEASES 
  Cancers are still one of the most detrimental diseases at present.3 Cancers can be 
defined as a group of diseases in which cells grow uncontrollable either in a specific 
organ or spread to other parts of the body. They may be caused by external factors, such 
as alcohol, radiation, and chemicals, and internal factors, including inherited mutations, 
hormone, and immune conditions. General prevention strategies for cancers may include 




















































































































































avoiding obesity, and considering chemoprevention. Detection and diagnosis of cancers 
varies among different types of cancers, but generally it is done by a series of screening 
and testing techniques for a specific type of cancer and further confirmed by biopsy or 
tissue examination.  
  Among the screening and testing methods, tumor markers are one of the targets 
used for early detection and diagnosis of cancers. Tumor markers are materials produced 
by tumor and other cells of the body induced by cancer and some select noncancerous 
conditions. Usually, these materials may be found in the blood and urine, and tumor and 
other tissues. Genomic and proteomic-based biomarkers are the most widely studied 
tumor markers for early detection of cancers. Genomic biomarkers are characteristic 
genetic mutations, or alterations in specific genes, while proteomic biomarkers are 
changes in protein shape, function, and pattern of expression due to cancerous conditions. 
Genetic alterations typically manifest themselves as the accumulation of multiple 
mutations in three types of genes: oncogenes such as K-ras genes,4 tumor suppressor 
genes of which p53 is an example,5 and DNA replication and repair genes.6 Compared to 
genomic biomarkers, protein biomarkers are much more complex due to the large total 
number of proteins in a cell, and the variations in proteins that exist among individuals, 
different cells, and even different stages of the same cell. Basically, protein biomarkers 
are very dynamic while genomic biomarkers are relatively static. Protein biomarkers can 
also be used for monitoring the progress of cancer diseases, the body’s response to drug 
treatment, and the relapse of cancer diseases.  
 Cancer researchers have so far achieved some success in promotion of the 
application of cancer biomarkers. For example, prostate specific antigen (PSA), a very 
specific protein biomarker for prostate cancer, has become an important clinical 
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screening target in the diagnosis of prostate cancer. For ovarian cancer which is usually 
diagnosed at an advanced stage, the main efforts have been dedicated in searching for 
early biomarkers such as those found in protein expression patterns between diseased and 
normal people.7 Combined investigations of three candidate proteins in blood have also 
proved to be helpful in differentiating between breast cancer from benign breast diseases 
and healthy controls.8    
In terms of treatment, cancer can be treated in various ways such as surgery, 
radiation, chemotherapy, immunotherapy, and hormones. Treatment is mainly determined 
by an overall evaluation of given cancer conditions by a physician and preference of the 
patient. For general information about cancers and their treatment, I refer you to the 
American Cancer Society (ACS) web site (http://www.cancer.gov/).  
1.3 THE BREAST CANCER PROJECT AT LSU 
  Breast cancer, one of the most burdensome cancers affecting women worldwide 
(second most detrimental in the US), possesses most of the characteristics of all other 
cancers. According to the most recent annual cancer report, approximately 1 in 8 women 
living today will be diagnosed of breast cancer in their lifetime. However, the occurrence 
rate is a function of geography: in high-risk regions such as North America and Western 
Europe it is 1 in 4 females, while it is as low as 1 in 16 females in areas such as China 
and Japan.  
Regarding prevention of breast cancer, the most updated data show obesity, 
exposure to alcohol, ionizing radiation, and hormone treatment all lead to an increased 
risk of breast cancer, while exercise is one of the factors that can actually decrease breast 
cancer occurrence. Chemoprevention, such as taking a drug named tamoxifen (a 
compound with both estrogen-like and anti-estrogen properties, or a selective estrogen 
 
8
receptor modulator) has proved to be effective in reducing the breast cancer occurrence 
or recurrence,9 but chemoprevention is only effective for women in high risk populations, 
and thus, it is not recommended for lower- and average-risk women because the possible 
harms may outweigh the benefits.10 Common screening techniques available for breast 
cancer include self-examination, mammography and clinical examination. It has been 
proved that mammography, a technique that has been used for almost 30 years, is able to 
produce much more sensitive results than self-examination and can locate tumors that are 
not commonly felt by self-examination; its implementation has been attributed to the 
decreased rate of breast cancer occurrence according to a recent survey (cancer facts and 
figures, 2006). Despite the fact that mammography has been the most frequently used 
modality for screening breast cancers it also produces false negatives, thereby failing to 
locate tumors in the breast, and also produces false positives, especially for dense-tissue 
breasts. Recent screening experiments have shown that magnetic resonance imaging 
(MRI) is more powerful and more sensitive than mammography, ultrasound, and clinical 
breast examination in detecting breast cancers.11, 12 Biopsy is an invasive technique 
because a small portion of tissue is removed while all other methods of detection are non-
invasive because no tissue will be removed for these tests. Although there is still some 
disagreement regarding which technique is more accurate, the most recent research by 
researchers in the Agency for Healthcare Research and Quality, a division of the U.S. 
Department of Health and Human Services suggests that noninvasive tests cannot replace 
the invasive test, i.e., biopsy, in order to get an accurate diagnosis because none of the 
non-invasive diagnosis techniques (mammogram, ultrasound, MRI, PET, 
Scintimammography) can eliminate false positives and false negatives. A summary of 
prevention techniques13 is listed in Table 1.1. For general information on breast cancers, 
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Treatment of breast cancer can vary for each and every individual, but nowadays 
the most commonly used treatment for breast cancer is comprised of radiation, 
chemotherapy, hormone, biological therapy, and surgery. As is true with most other 
cancer diseases, it is often futile and disfiguring to treat the cancer when it reaches its 
advanced stages. Therefore, it is crucial to develop techniques that are capable of 
detecting breast tumor formation accurately at its earliest stage and subsequently take 
appropriate measures for treatment.14 Strategies for early diagnosis of breast cancer or 
Table 1.1 Detection and Prevention Recommendations for Breast Cancer.  





1-2 year beginning  at 
age of 40 years 
BRCA mutation carriers: monthly self-
examinations beginning by age of 18-21, 
annual or semiannual clinical examinations 
beginning at age 25-35 years old, and 
annual mammography beginning at age of 
25-35 years old.  
Ovarian cancer 
screening 
No screening BRCA1 mutation carriers: annual screening 
using transvaginal ultrasonography and 
CA-125 serum levels beginning an age of 
25-35 years old; optional for BRCA2 
mutatoin carriers.  
Chemoprevention 
for breast cance 
None Women at increased risk for breast cancer 
as defined by the Gail model and low risk 





None Women with ≥ 2 first-degree relatives with 
ovarian cancer: offer prophylactic 
oophorectomy after completion of 
childbearing or at age of 35 years old.  
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breast cancer predisposition are usually carried out by screening for genetic mutations in 
genetic biomarkers, especially for high-risk populations, examining proteomic 
biomarkers such as Her2/neu, CEA, MUC-1, and mammoglobin. Genes that have been 
identified to be related to hereditary breast cancer are BRCA1, BRCA2, TP53, CHK2 and 
ATM, and they are generally involved in the maintenance of genomic integrity and DNA 
repair. Mutations in these genes usually result in truncated or malfunctional respective 
proteins in breast or ovarian tissues.15 A comprehensive breast cancer mutation database 
can be found at the Breast Cancer Information Core (BIC) website 
(http://research.nhgri.nih.gov/projects/bic/). Around 10% of breast cancers are caused by 
inherited genetic mutations (or abnormal genetic sequences), among which are mutations 
in two most commonly involved genes, namely Breast Cancer Type I Gene (BRCA1) and 
Breast Cancer Type II Gene (BRCA2), while a higher risk is found with those having 
BRCA1 abnormalities. People who inherit mutations in this gene will have a higher risk 
of developing breast cancer (50-85% chance of developing breast cancer in their 
lifetime16) as well as others, such as ovarian cancer. The BRCA1 gene, which expresses a 
specific protein in breast and ovarian tissue, has been found to be a DNA damage repair 
and tumor suppressor gene,17 meaning that, at its normal stage, it maintains normal cell 
growth of breast tissue and suppresses tumor formation through the process of protein 
expression.  
Several of the most common and characterized protein biomarkers for breast 
cancers are listed in the following Table 1.2. The majority of proteins are membrane 
proteins and as a result have unique features. Displayed in Figure 1.4 is a schematic of 
different types of membrane proteins. Her2/neu, carcinoembryonic antigen (CEA), 
MUC-1 or CA15.3, mammaglobin have been found to be associated with breast cancer. 
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MUC-1 (CA15.3, a carbohydrate antigen marker), one member of the transmembrane 
mucins family, is found to be over-expressed in various human carcinomas including 
breast cancer carcinoma.18, 19 Mammaglobin, a member of a protein family recently 
designated as secretoglobins, has been identified as a serum-born breast cancer 
biomarker, and studies of the protein have shown that 70-80% of breast tumors are 
positive for it.20 Her2 is referred to human epidermal growth factor receptor 2 and also 
known as neu, Her-2/neu and c-erbB-2. This is a transmembrane glycoprotein, of which 













domain has tyrosine kinase activity, while the extracellular domain (97–115kDa) is shed 
into the circulating body fluid and can be measured to test the expression level using 
serum samples.21 Her-2 overexpression is associated with a number of cancers although 
most investigations have been focused on breast cancers. Her-2 positive breast cancer 












Figure 1.4 Schematic of cross section of biological membrane. 
 
12
tends to result in a lower survival rate than Her-2 negative type. The Her-2 positive type 
of breast cancer is a candidate for treatment by trastuzumab (brand name Herceptin), a 
very specific monoclonal antibody against Her-2 antigen. Her-2 was initially found to be 
correlated to breast cancers at advanced stages with protein overexpression identified in 
10-34% of invasive breast cancers.22 Her-2/neu amplification was also detected at a very 
low level and proved to be a valuable biomarker for early stage breast cancer.23 CEA was 
the first identified human tumor biomarker and is one of the most thoroughly 
characterized tumor associated antigens.24, 25 CEA has one IgV-like and a variable 
number of Igl-like domains, a putative transmembrane domain, and a cytoplasmic tail 
which can be replaced by a glycosyl phosphatidylinositol anchor. CEAs are encoded 
from the chromosome 19q branch, which form a family gene cluster (at least 20 genes 
including CEACAM1 to CEACAM8, CEACAMP1 to CEACAMP11and PSG). The 
cellular functions of CEA consist of homophilic adhesion, heterophilic adhesion, E-
selectin binding, tumor suppression, type I fimbriae binding, and transmembrane 
signaling.26 The CEA structure27 is illustrated in Figure 1.5.   
 In terms of clinical relevance, overexpression of CEA has been found in 
various types of tumors, including those from the colon, breast, and lung.28 CEA is 
especially valuable for evaluation and monitoring of metastatic breast cancer because 
protein overexpression was found in the serum of about 40-50% of patients.29 However, 
the percentages of cases targeting elevated levels of CEA in early breast cancer 
development vary considerably, primarily depending on the primary tumor site.30, 31 In 
addition, serial CEA levels are of particular clinical importance and are persistently 
elevated (>10 ng/mL) in cases of relapse.32 The mostly used serum-born protein 



























Figure 1.5 Schematic of CEA structure. The molecular weight of CEA is raised up to 
180kDa due to glycosylation.  
Table 1.2 List of most widely used serum tumor markers in breast cancer.  
Marker                                                          Protein(s) detected
CA 15.3                                                         MUC-1
BR 27.29 (CA 27.29)                                           MUC-1
CEA                                                             CEA
TPA                                                             Fragments of cytokeratin 8, 18, and 19
TPS                                                             Fragments of cytokeratin 18
Her-2 (shed from)                                               Extracellular form of Her-2
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In summary, each of the biomarkers, either gene or proteins, can provide some 
assistance in prevention, diagnosis, prognosis, and monitoring the treatment of breast 
cancer, but none of them is by itself conclusive enough to evaluate the status of the 
disease. Thus a novel analytical platform is urgently needed where multiple biomarkers 
from different classes can be assayed with high sensitivity and specificity.  
1.4     STRATEGIES FOR DISCOVERY AND EARLY DETECTION OF BREAST 
CANCER BIOMARKERS 
Since it was initially mapped to chromosome arm 17q in the early 1990s,34, 35 
considerable efforts have been devoted to BRCA1 research including development of a 
reliable, inexpensive, accurate, and sensitive testing methods, such as a combination of 
PCR amplification and 2-D electrophoresis36 and fluorescence-assisted mismatch 
analysis for screening.37  
Microarray technology has also been extensively explored for detection of 
mutations in the breast cancer related gene BRCA1.38-40 In these reports, all BRCA1 
coding exons from genomic DNA were PCR amplified using intronic forward and 
reverse primer pairs containing T3 and T7 promotor sequences to allow transcription 
using RNA polymerases and biotinylated or fluorescently labeled dUTP analogs to 
permit detection.  These transcribed RNA targets were then hybridized to the BRCA1 
array, and two-color imaging was implemented to obtain information in regards to the 
polymorphic nature of specific sites in the coding regions.  
Screening tests on BRCA1 and BRCA2 genes, especially among high-risk 
populations, have been more and more acceptable to the public. Appropriate measures, 
such as adjustment of lifestyle, undergoing chemoprevention, and mastectomy (surgery 
to remove the affected breast) would be taken by people if diagnosed of carrying 
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mutations in these genes. A great amount of effort has been devoted to developing 
practical, inexpensive, fast, sensitive, and accurate techniques for screening gene 
variations of particular connection to cancer diseases. The common strategies used for 
analyzing genetic mutations can broadly be categorized into two different types, direct 
and indirect.41 Direct methods, which include DNA sequencing, document the existence 
of the particular mutation and also reveal its exact nature (A, C, G or T in the case of 
single-point-mutations).  Indirect methods typically screen large sections of genes for 
mutations but do not provide information relating to the exact composition of the 
mutation. Techniques commonly performed for screening mutations in these two breast 
cancer related genes are summarized in Table 1.3.15 As noted in Table 1.3, there are a 
number of potentially powerful techniques to analyze various types of mutations in 
BRCA1 or BRCA2, all possessing particular advantages and disadvantages. For example, 
the protein-truncation test (PPT),42 an in vitro translation technique, has been used 
mainly for searching for small-insertions or deletions, or nonsense mutations that lead to 
the introduction of a stop codon,14, 43-45 and hence a result of truncated proteins. This 
technique is fast and inexpensive but not very sensitive, so it is limited to screening only 
for mutations in large exons, such as exon 11 in the BRCA1 gene, and exon 10 and 11 in 
the BRCA2 gene.15  
Since it was developed in mid 1990s,46 denaturing high-performance liquid 
chromatography (DHPLC) has proved to be a promising, sensitive, and cost-effective 
technique for detecting genetic alterations predisposed for a particular disease.47 It has 
since attracted interest from various fields and has been applied to identifying mutations 
related to a variety of genetic diseases, such as NPM1 mutations in acute myeloid 




















In comparison to the conventional HPLC method, this technique involves a 
unique stationary phase (DNASep, Transgenomic Inc., San Jose, CA) made of alkylated 
nonporous poly(styrene-divinylbenzene) particles 2-3 microns in diameter, which enables 
the separation of nucleic acids by means of ion-pair reverse-phase liquid 
chromatography.50 Briefly, the principle governing the separation of nucleic acid with 
DHPLC is that the positively charged triethylammonium ions are adsorbed at the 
interface between the nonpolar stationary phase and the hydroorganic mobile phase, and 
Table 1.3 Techniques used to detect mutations in BRCA1 and BRCA2.  
 Technique   Advantages  Disadvantages  
Protein-truncation test  Cheap; rapid; allows 
detection of genomic 
deletions 
Mutations can be missed when 
gene product is very short; does 
not missense mutations; RNA 
required to examine small exons
Single-strand-conformation 
analysis of genomic DNA 
Simple; well-established 
techniques 
Low sensitivity; labor-intensive; 




Detects almost all intra-
exonic and splice-site 
mutations; rapid 
Expensive equipment required; 
does not detect exon deletions 
DNA chips Can potentially identify 
all sequence variants; 
very rapid 
Expensive equipment required; 
high cost per chip 
Direct sequencing Identifies most intra-
exonic and splice-site 
mutations 
Expensive; exon deletions can 
be missed if detailed  
single-nucleotide-polymorphism 








therefore leads to a positive stationary phase surface potential and retention of dsDNA 
results from electrostatic interactions between the positive surface potential on the 
stationary phase and the negative charges of the phosphodiester groups of the dsDNA. 
Despite all the advantages of DHPLC, it needs to be coupled to other techniques to 
determine base compositions, and further development is necessary to make it more 
amenable and quantitative in order to reach gene mapping levels. 
The most sensitive and reliable gene screening technique is probably direct 
sequencing because this technique is able to provide detailed base information 
quantitatively; it is, therefore, especially useful as a screening of genetic mutations 
corresponding to particular cancer diseases. Unfortunately, it is often technically 
demanding, costly, and time-consuming. Researchers have invested significant effort in 
finding fast, sensitive, friendly techniques for detecting alterations in large genes as 
alternatives of direct sequencing or prior to sequencing. Gross and coworkers compared 
mutation analysis on BRCA1 gene using direct sequencing, single-strand conformation 
polymorphism (SSCP)51 and DHPLC, and found out that DHPLC resolved 100% of the 
DNA alterations while SSCP detected 94% variations as were observed in cyclic 
sequencing. 
Single-strand-conformation analysis of genomic DNA (SSCA) is a technique 
traditionally used in locating gene alterations. It has been used to successfully detect 
mutation spectrum in Danish young female breast cancer patients by screening regions of 
BRCA1 and BRCA2 genes.52 
Multiplex ligation-dependent probe amplification (MLPA) is another quantitative 
technique that has been proved to be powerful in determining multiple deletions and 
duplications in BRCA genes simultaneously in a single reaction.53 In brief, this technique 
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involves two probes hybridized to the target sequence (genomic DNA) and joined 
together by a ligase to make a copy of that sequence. The probes are so specially 
designed that all the sequence products will be amplified using the same pair of primers. 
This feature contributes to the simultaneous nature of this amplification technique, but 
this technique cannot detect intra-exonic mutations. 
 In general, most of the screening techniques described above involve a PCR step 
to amplify the genomic DNA materials preceding the sequencing, followed by gel 
electrophoresis to analyze the fidelity or to identify the compositions of the sequencing 
target. It turns out that all of these techniques are labor intensive, and some, such as 
SSCA, cannot provide sufficient levels of sensitivity. 
During the past one and a half decades, a new technique named oligonucleotide 
arrays, or DNA chips has evolved, and it is clear that this is a powerful tool in acquiring 
genomic information in a parallel, rapid fashion.54  Since the pioneering work by Fodor 
and coworkers in the early 1990s on light-directed spatially addressable combinatorial 
chemical synthesis of oligonucleotides,55 which makes high density oligo arrays possible 
and readily available (Affymetrix), DNA chips have found numerous applications from 
rapid DNA sequence analysis54 and mutation detection in various types of genes38, 56-59 to 
gene expression monitoring,60 gene function analysis,61 and even optimization of 
antisense oligo design.62 Generally speaking, this technique is based on the 
differentiation of fluorescence signals between perfect-matched hybridization reactions 
and mismatched hybridization reactions; it is so sensitive that it can detect single-base 
pair mismatch among targeting sequences due to the high density, highly diversified 
probes arrayed on the chip surfaces. Specifically for breast cancer, microarrays, or DNA 
chips have found diverse applications, such as monitoring chromosome gains and losses, 
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tumor classification, drug discovery and development, DNA resequencing, mutation 
detection and investigation of the mechanism of tumor development.63 
To summarize, a variety of practical techniques used for screening BRCA genes in 
identifying predisposition mutations has been developed, and this has to date served the 
increased request for gene screening by high-risk populations. Nevertheless, there is still 
a desperate need to find appropriate antibodies against BRCA1 to evaluate protein levels 
in normal and tumor tissues, but sadly the so-far-raised antibodies against various 
epitopes on BRCA1 have not been proved valuable yet by immunohistochemical (IHC) 
analyses due to their low reproducibility.15 Moreover, genetic markers may in some cases 
not suffice to correctly identify a specific phenotype, especially in the early stages of 
tumor development due to the static nature of the cell’s genome.  Therefore, it is 
desirable to look at protein expression levels because the proteome (entire complement of 
proteins expressed by a single cell, tissue or organ) profile is highly dynamic (responds 
quickly to external stimuli), and it is the proteins that comprise the proteome that regulate 
processes resulting in the phenotype. 
In general, screening for protein expression qualitatively is done by Two-
dimensional gel electrophoresis, following extensive sample preparation to isolate 
interested protein types.64 Two-dimensional (2-D) gel electrophoresis typically involves 
carrying out isoelectric focusing based on the isoelectric point of each protein component 
along one axis, then sodium dodecylsulfate (denaturing) poly(acrylamide) gel 
electrophoresis (SDS-PAGE) along the second axis to further differentiate proteins 
according to molecular weights. Following 2-D separation, staining of the gels to label 
the separated proteins is achieved using coumassie blue or silver ion. This modality has 
been the classic way for protein mapping analysis for years, but it has become less 
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popular as a result of its limitations of poor dynamic range, the associated intensive labor, 
long analysis times, and irreproducibility. Moreover, due to the diverse nature of various 
protein components, this technique requires pretreatment of samples, such as 
fractionation via isoelectric focusing.65 Therefore, much effort is being invested into 
developing automated methods for analyzing proteomes,66, 67 among which are DNA 
microarray techniques developed recently to study proteomics based on the assumption 
that mRNA transcription levels correlate well with the corresponding protein translation 
levels; however, this genomic-based proteomic study has proved to be in poor 
correlation.68, 69  
Protein chips, or protein microarrays have replaced DNA microarrays in the study 
of proteomics and implementation in the development of biologically integrated devices, 
and thus, they have become a viable alterative to two-dimensional gel electrophoresis on 
protein expression profiling analysis.70 Protein microarrays, or protein chips are nothing 
more than a spatially defined immobilization of proteins on a solid substrate (protein 
patterning). This technique was originated in the mid 1980s when researchers tried to 
integrate biomolecules into miniature biological-electronic devices.71, 72 Commonly used 
techniques for creating protein arrays (micron or nanometer scale73, in 2-D or 3-D) on 
surfaces include use of conventional photoresist lithography,74, 75 photochemistry,76-78 
self-assembled monolayers (SAMs),79-81 and dip pen nanolithography.73 Protein chips are 
normally analyzed by transduction of detectable fluorescent signals82 and by use of 
imaging techniques, such as scanning electron microscopy (SEM),83 atomic force 
microscopy (AFM)84, 85 and time of flight-secondary ion mass spectrometry (TOF-
SIMS).82, 86 Protein chips have also been implemented in detection of tumor 
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biomarkers,87 and protein profiling for differentiating normal or pre-malignant cells from 
cervical cancer cells.88  
Mass spectrometry has recently entered the proteome research arena and it is clear 
that it has great capability and potential—especially when it is coupled with other 
conventional or non-conventional techniques—in identification and quantification of 
protein expression levels from cells, tissues, and other organisms. Traditionally matrix-
assisted laser desorption/ionization-mass spectrometry (MALDI-MS) has been combined 
with two-dimensional gel electrophoresis for peptide fingerprinting after in-gel 
proteolytic digestion.89 A modified version of 2-D separation coupled with mass 
spectrometry was recently reported in which a 2-D liquid phase separation method 
composed of isoelectric focusing in one dimension and non-porous silica reverse-phase 
high-performance liquid chromatography as another, was coupled to electrospray 
ionization-time of flight mass spectrometry (ESI-TOF MS); this led to successful 
recognition of potential breast cancer biomarkers from cell lysates of breast epithelial cell 
lines.89     
Not only has mass spectrometry been coupled to 2-D separation techniques in the 
study of proteome, it has also been combined with protein biochips, and has proven to be 
an even more powerful tool in identification, differentiation and quantification of 
proteins, especially biomarkers used in diagnosis and monitoring of cancer diseases.88 
Protein chips together with surface enhanced laser desorption/ionization (SELDI) mass 
spectrometry, has successfully detected prostate cancer biomarkers in complex protein 
mixtures.90 In fact, 2-D separation, mass spectrometry, and protein biochips have formed 
an indispensable technical triade in proteomics;91 it will be interesting to see what 
powerful things it can achieve in years to come. 
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While a large fraction of the aforementioned strategies allow for study of many 
different target proteins, it is not really necessary in some cases, especially when 
investigations are carried on readily defined biomarkers, whether they be nucleic acids or 
proteins. It is more appropriate to target only those biomarkers for diagnosing and 
monitoring diseases; large-scale screening does not actually add any significant 
information. As such, the single-element biosensor platform has become important in the 
arsenal of tools for diagnosing cancers and monitoring its treatment. This type of 
biosensor system is typically comprised of a specific biosensing film on which a 
biological probe is immobilized on the support, and a measurable signal (transduction) is 
generated upon interaction of the probe with a target molecule. For instance, in an 
immunoassay (in forward format), an antibody (Ab) is attached on a solid substrate to 
capture its specific antigen (Ag), and the signal readout will be analyzed upon 
introduction of a secondary Ab that carries a fluorescent dye, or another type of tag, such 
as an enzyme or electrochemically active groups. In a protein sensor, the target protein 
can also be differentiated from interfering protein components by the differing transduced 
signal intensity in a protein assay. In the case of DNA sensors, a nucleic acid probe 
(typical length of 24 mer) is chemically tethered to the sensor surfaces and hybridized to 
its target sequence; the presence of mutations or mismatches in the target and probe 
sequences result in a signal which can be differentiated from the fully matched 
hybridization sequence pair.  
For breast cancer, a number of biosensor platforms for detection of and 
monitoring biomarkers have been developed. For example, Wang and co-workers 
reported a silicon-based ultrasonic immunosensor for detection of breast cancer antigens 
CA15.3 in the sera of breast cancer patients.92 The sensor is composed of a flexural plate 
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wave gravimetric platform where CA15.3 antibodies were immobilized on the plate 
surfaces. Upon association with CA15.3, a mass increase resulted. Wang and Kawde 
developed a pencil-based biosensor for label-free electrochemical detection of DNA 
hybridization events.93 In this work, a tiny electrode (pencil lead) was electrochemically 
loaded with the DNA probe which consisted of an inosine-substituted E908X-WT 
oligonucleotide to detect point mutations in BRCA1 gene. The authors demonstrated that 
they were able to discriminate between fully matched and single-base mismatched 
duplexed DNA by measuring the electrochemical signal generated from the sensor 
system.   
1.5 STRATEGIES FOR MULTIANALYTE ASSAYS 
  In order to provide the ability to accurately detect early onset of breast cancer, a 
sensor system which is able to simultaneously determine the presence of known 
biomarkers for this specific cancer is highly desired. Detecting or sensing multiple 
analytes without a pre-detection separation step has always been an endeavor for 
researchers in the sensor development arena. The general principle for sensing detection 
with a recognition probe is based on some type of specific interaction between the target 
molecules and the capturing probes that are immobilized on a substrate surface. There are 
two these types of specific assays, namely antibody-antigen interaction-based and DNA-
DNA pairing interaction-based, both of which depend on reversible, non-covalent 
bonding forces (hydrogen bonding, and/or hydrophobic interactions, electrostatic, and 
van der Waals interactions). Assays that are based on antibody-antigen interactions are 
called immunoassays, or solid-phase immunoassays. Normally, specific antibodies are 
immobilized on a solid substrate to capture specific antigens (target molecules in a 
sample matrix) and analyzed through signal generation methods that employ a trace 
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antibody, or detection antibody, that are labeled with a fluorescent dye to form a 
sandwich immunoassay (non-competitive immunoassay), or through a competitive 
immunoassay format, such as a displacement immunoassay.  
 Incorporating multi-analyte assays into the same platform has been studied 
extensively and is being pursued by some research groups summarized in Table 1.4,94 
among which are Ekins, et al.,95 and Kakabakos, et al.,96 who first developed the concept 
of multianalyte immunoassay (MAIA) using confocal and time-resolved fluorescence 
microscopy respectively. Plowman and coworkers reported a multiple analyte 
immunoassay based on an integrated optical waveguide sensor in which multiple 
antibodies were patterned on a planar waveguide to bind target antigens in the sample 
matrix. The transduced signals were generated by introducing multiple detection 
antibodies to form sets of sandwich immunocomplexes.94 Frances Ligler’s research group 
at the US Naval Research Laboratory has invested significant efforts in the sensor 
research arena, especially in regard to a variety of multianalyte biosensor platforms.97-103 
A typical direction in Ligler’s work is the use of a polydimethoxysilane (PDMS) stamp 
with parallel channels, was used to immobilize the capture molecules, protein (Ab), or 
ligand. Another similar PDMS stamp with channels running perpendicular to those in the 
first stamp was sealed to the substrate surfaces tightly, and targeting agents and 
fluorescently labeled detection ligands were flowed through these channels. The glass 
microscope-based waveguide was used in conjunction with a CCD camera, a laser, and a 
few other optical components to yield a fluorescence reader system capable of reading 
out fluorescence intensity as a function of positions.104  
It is important to point out that Ligler’s group not only has extensively researched 
and applied their biosensor systems to various targeting agents, such as toxins, bacteria, 
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viral, and proteins, but has also investigated different substrates used for building the 
biosensor system. The substrate material used for building the waveguide arrays range 
from the initially used glass-based support to the more recently adopted polymeric 
material, in which they have been attempting to incorporate the newly evolved polymer-
based BioMEMS concept into the multianalyte biosensor system.1, 105, 106 Interestingly, 
all the biosensor work reported from Ligler’s group, whether it be based on single- or 
multiple-analyte assays, predominantly utilizes fluorescence as the detection methods 

















Table 1.4 Examples of multiple analyte immunoassays.  
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In addition to fluorescence there are some other types of optical methods for 
interrogating biosensing films, including the so called label-free techniques, such as 
interferometry, resonant mirror, and metallic waveguide, or surface plasmon resonance107 
Electrochemical methods are third in popularity in the biosensor arena. Wilson and 
coworkers reported electrochemical multianalyte immunoassays using an array-based 
sensor based on eight iridium oxide sensing electrodes possessing four different 
antibodies, an iridium counter electrode, and a Ag/AgCl reference electrode, all of which 
were patterned on a glass substrate. Single generation and transduction of protein targets 
were achieved by ELISA, measuring hydroquinone generated by electrochemical 
oxidation.108 There are still other strategies associated with analyzing multiple targets 
simultaneously, such as those performed on the microfluidic platforms; these will be 
discussed in detail after a brief introduction to BioMEMS technology.    
 In addition, there are also a few commercially available biosensor systems that 






1.6  MULTIANALYTE ASSAYS ON MICRODEVICES 
 The area of miniaturized devices more commonly known as lab on a chip, or 
micro total analysis systems (μTAS) has seen rapid growth both in academia and industry 
in recent years. The first analytical miniaturized device was actually developed as early 
as the 1970s when a silicon-based gas chromatographic analyzers were reported by 
Table 1.5 Commercially available multianalyte sensor system.  
Company System  Fluidic  Automation  Detection 
Biacore SPR Four  Partial  Mass change 
IGEN ORIGEN Free solution Partial  Magnetic  
Fisons Affinity Sensor IAsys Cuvette (2)  Partial  Resonance  
Lifepoint IMPACT Minicolumns (10) Partial  Fluorescence 
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researchers from Stanford109, 110 and IBM.111, 112 These reports did not initially attract 
much attention from the research community, probably there was not the need for 
miniaturized separation science methods then, people did not anticipate the significant 
breakthroughs possible as a result of miniaturized devices. It was not until 1990 when 
Manz proposed the miniaturized total chemical analysis systems concept113 that the area 
of miniaturized devices reemerged; subsequently this area has rapidly developed into a 
field of its own as a result of the efforts of various research groups all over the world. 
μTAS, or lab-on-a-chip has seen a dramatic increase in growth especially after the mid 
1990s when more research groups joined the endeavor to develop this area. The 
applications of such “chip-based” devices have also broadened, such as the dominant 
application of separating nucleic acids, amino acids or/and other species, the more 
specialized separations,114, 115 cell manipulation,116 bio- and chemical reactors,117-123 and 
even miniaturized mass spectrometers.124 Biological microelectromechanical systems 
(BioMEMS), which fall among the commonly known category of “lab-on-a-chip”, or 
μTAS, resulted from the marriage between integrated circuits and biotechnology, on 
which both electrical and mechanical components (typically in micrometer size) are 
integrated and directed for biochemical and chemical assays.  
 Microfabrication of BioMEMS devices has mainly accomplished using chemical 
etching and lithography because the substrate used was predominantly glass or silicon at 
the early stage of the BioMEMS area. More diverse substrate materials have come into 
this field in recent years, and polymers (plastics) have attracted more and more attention 
because there are a variety of microfabrication technologies amenable for polymers that 
make device fabrication via mass production a tractable option. Microfabrication in 
polymers consists of hot embossing,125 injection molding,126 imprinting,127 laser 
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ablation,128 and soft lithography.129, 130 Initial applications of polymer-based BioMEMS 
were in the separation field and gradually expanded to many other areas such as 
immuosensor systems.131 Immunoassays can be performed in microfludic chambers by 
immobilizing antibodies covalently or by adsorption on the surface of the microdevice, 
flowing in the targeting proteins, and tranducing the signal with optical, electrochemical, 
or other techniques. Multianalyte assays using microfluidic platforms have also been 
made possible, especially with the advent of soft lithography technologies. In the 2005 
review of microfluidic techniques in microarray applications by Grodzinski and others,132 
several strategies were summarized that target multianalyte assays mainly directed 
towards nucleic acid analysis. In one strategy, multiple nucleic acid probes were 
patterned by a soft stamp usually made of PDMS, followed by hybridization with their 
complementary sequences introduced by another perpendicularly aligned PDMS stamp, 
followed by detection with either optical or electrochemical methods. Using these 
strategies, high density arrays can be made or high complexity can be achieved to 
analyze many different targets. Depending upon the needs of the device with respect to 
array density, multiple nucleic acid probes can in fact be directly spotted onto the 
microchannel before sealing the device, and then interact with a mixture of targeting 
sequences introduced into the sealed channel. Patterning proteins or antibodies on 
microfluidic devices to perform multianalyte assays or specifically multianalyte 
immunoassays have also been achieved in the same concept as that with nucleic acids.131      
1.7 HYBRID MULTIANALYTE ASSAYS IN MICRODEVICES 
   As can be seen from the previous section, all the multianalyte assays are directed 
towards the simultaneous detection of the same type of analytes—either proteins or 
nucleic acids. There has not been much investigation of the hybrid multianalyte assays, in 
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which different type of targeting agents can be analyzed on the same platform 
simultaneously, due to the fact that there exist significant biases among different targets 
in terms of surface immobilization methods, choice of biological buffer systems, and 
reaction conditions. 
  In the following research work, a novel strategy to simultaneously analyze both 
protein antigens and gene sequences will be presented. In this strategy, a universal DNA 
microarray is fabricated using the mature PDMS patterning technique. Gene mutated 
materials and the protein antigen target are captured by hybridization interactions, and 
then signals are generated by near-IR, laser-induced fluorescence. Pre-treatment of both 
gene and protein targets are carried out; gene target materials are prepared using 
PCR/LDR combined assays which incorporate the complementary Zipcode DNA 
sequence and the near-IR fluorescent tag into the target sequence, while protein target 
materials are semi-synthesized to form a complex that carries a complementary Zipcode 
DNA sequence and a sandwich immunoassay. 
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CHAPTER 2.  PHOTOCHEMICALLY PATTERNED POLY(METHYL  
METHACRYLATE) SURFACES USED IN THE FABRICATION OF 
MICROANALYTICAL DEVICES* 
2.1 INTRODUCTION 
Biological microelectromechanical systems (BioMEMS) have attracted 
significant interest in recent years due to their potential impact on biological analysis, 
drug development, and medical diagnostics.1-5 The promise of BioMEMS in instrument 
development and assay methodologies is associated with the intrinsic advantages of 
BioMEMS, such as small footprint and easy multiplexing, and with the potential for 
integration of various components into the system, as well as mass production of the 
devices at an attractive cost. Since the first fabrication of micro-electrophoresis devices 
in glass substrates using photolithography and wet chemical etching,5, 6 various 
microdevices have been constructed and used for bioanalytical applications, such as PCR 
amplification of oligonucleotides,7, 8 separation of single-stranded9-11 and double-stranded 
DNA,12-15 and protein analysis.15, 16  
Most of the early BioMEMS devices were made of glass, quartz, or silicon 
because of the well-established micromanufacturing techniques and surface chemistry of 
silicon and silicon oxides, their rigidity, and optical properties.17, 18 The use of polymer 
substrates in the construction of BioMEMS devices has become increasingly important 
because microstructures, including those with high aspect ratios, can be readily produced 
in polymers using rather straightforward processing methods.19, 20 In addition, massive 
fabrication of most parts of polymer-based BioMEMS devices can be achieved using 
various techniques such as laser ablation,21 injection molding,22 hot embossing,23 
* reproduced with permission from Journal of Physical Chemistry B, Volume 109, issue 35, pages 16988-
16996, 2005. Copyright 2006 American Chemical Society.  
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imprinting,24 and soft lithography.25, 26 Moreover, the relatively low glass transition 
temperature (Tg) of most polymers should make it possible to attach biomolecules before 
devices are assembled (thermal annealing), which cannot be achieved in SiO2-based 
devices because of the high glass transition temperature (Tg > 600 °C) of this material. 
Poly(methyl methacrylate), PMMA, a thermoplastic polymer, is one of the primary 
polymeric materials that has been used for fabrication of microstructured devices.19, 27, 28  
Due in part to the high surface-to-volume ratio, surface characteristics, such as 
wettability, surface topography, and interfacial charge density and distribution, are 
crucial factors that govern the functional capabilities of BioMEMS devices.29-32 Chemical 
modification techniques for SiO2-based devices are well established using silane-based 
chemistry,17 but a wide variety of routine, simple, and well-defined surface modification 
protocols for polymers used in BioMEMS applications is needed.28, 33, 34 Preformed 
PMMA microchannels have been modified using a pulsed UV excimer laser to reduce 
band broadening effects in electrophoretic separations,34 and poly(carbonate) 
microchannels have been made “more hydrophilic” by UV irradiation.35 PMMA surfaces 
have also been made more water wettable by direct amination,29 vapor-phase deposition 
of organic films,36 copolymer grafting,37 or by formation of molded devices via photo- or 
thermo-polymerization of co-monomers.38, 39 In addition, it has been shown that PMMA 
surfaces can be readily patterned through techniques such as photo-directed electroless 
deposition,39 photoinitiated grafting,40 and exposure to deep UV sources.41, 42 
Electroosmotic flow was also controlled by either UV laser ablation in preformed PMMA 
microchannels,34 or PEG grafting after PMMA surfaces were activated by oxygen plasma 
treatment.43 Continued expansion of surface modification routes is essential to the 
development of BioMEMS technologies based on polymer substrates. 
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Reported here is a photochemical surface modification protocol for PMMA, a 
well-known substrate material for the fabrication of BioMEMS devices. It has been found 
that surface carboxylic acid groups are formed upon UV exposure of PMMA surfaces in 
the atmosphere (surface photochemical modification), and the resulting surface 
carboxylic acids allow for further functionalization of PMMA-based BioMEMS 
devices.44 Surface properties of the PMMA for each step of treatment process are 
systematically investigated—qualitatively and quantitatively—by water contact angle 
measurements, scanning force microscopy, X-ray photoelectron spectroscopy, 
fluorescence microscopy, and specific functional group labeling. In addition, the effect of 
UV modification on electroosmotic flow in hot-embossed PMMA microchannels is 
demonstrated. Finally, based on the outcomes from deconvolution of X-ray photoelectron 
spectra of pristine and UV-exposed PMMA surfaces, a possible mechanism for the 
photochemical carboxylic acid formation is discussed. 
2.2 MATERIALS AND METHODS 
2.2.1  EXPERIMENTAL 
2.2.1.1 GENERAL 
Poly(methyl methacrylate) sheets, Plexiglass or Lucite, were purchased from Goodfellow 
and AIN and were machined to various-sized pieces.  Before any type of experimental 
analysis was carried out, PMMA pieces were sonicated in isopropanol (IPA) for 15 min, 
then rinsed with IPA and subsequently dried with a flow of house nitrogen; scanning 
force microscopy did not indicate any increases in surface roughness as a result of this 
cleaning protocol. HPLC-grade isopropanol (IPA) and all other chemicals were obtained 
from Aldrich and used without any further purification unless noted otherwise.  The UV 
light source used here is a low-pressure mercury lamp possessing an emission spectrum 
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spanning the 240 nm to 425 nm range; the 254 nm band is the strongest with an intensity 
of 15 mWcm-2, while that of all others is less than 1.5 mWcm-2 at a 1-cm distance. The 
microfluidic electrophoresis devices were fabricated using a method previously 
developed.45 In brief, a metal molding die, which consists of raised microstructures 
electroplated from Ni on a stainless steel base plate, was made using the X-ray LIGA 
technique.19, 45 PMMA microstructures were embossed in a system that consisted of a 
PHI Precision Press (model number TS-21-H-C (4A)-5; City of Industry, CA), in which a 
vacuum chamber was installed to produce low pressure (<0.1 bar) for complete filing of 
the Ni molding die. During embossing, the molding die was heated to 150 oC and pressed 
into the sheet PMMA at 1000 lb for 4 min. The PMMA part was then cooled to 85 oC for 
demolding. The embossed PMMA substrate (0.5-cm thick) was annealed to a piece of 
PMMA cover plate (0.05-cm thick) to enclose the microfluidic channel, which was 
achieved by clamping both parts with glass plates and heating at 105oC in a convection 
oven for 15 min. To make UV-modified (carboxylic acid-modified) PMMA 
microchannels, the embossed PMMA substrate was first exposed to UV light for 30 min 
then rinsed with IPA. The cover plate was also processed in a similar fashion, and both 
PMMA pieces were then annealed at 98 oC for 15 min in the oven described above. The 
microfluidic electrophoresis device consists of cross-flow channels with a separation 
channel length of 4 cm, a channel depth of 100 μm, and channel width of 50 μm. 
2.2.1.2 CONATCT ANGLE MEASUREMENTS 
Sessile water contact angle measurements were used to probe the effect of UV 
exposure on the surface hydrophilicity of PMMA. Contact angle values on PMMA 
surfaces were obtained with a VCA 2000 contact angle system equipped with a CCD 
camera (VCA, Billerica, MA).  Approximately 2 μL of deionized water (18 MΩ cm) 
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were placed on the PMMA surface using a syringe, and the contact angle of the water 
droplet was measured immediately using the software provided by the manufacturer.  The 
measurements were repeated at least five times at separate positions on a given substrate, 
and the values here are reported as the mean ± one standard deviation.  
2.2.1.3 SCANNING FORCE MICROSCOPY (SFM) 
The surface topographies of the pristine/unmodified and UV-modified PMMA 
surfaces were assessed using a Digital Instruments Nanoscope III multimode scanning 
force microscope in non-contact (Tapping) force mode.  The images presented were 
treated by use of the flatten algorithm using the Nanoscope software. RMS roughness 
was calculated using the software provided by the vendor. 
2.2.1.4 CHEMICAL MAPPING OF THE FUNCTIONALITIES INDUCED BY 
PHOTOLYSIS ON PMMA SURFACES 
The protocol is outlined in Scheme 2.1 and is as follows: a piece of PMMA sheet 
(2.54 cm x 7.62 cm x 0.05 cm from AIN Plastics) was ultrasonicated in isopropanol for 
15 min, rinsed with isopropanol (IPA), and dried with house N2. The sample was placed 
on a microscope slide and a 2000 mesh Ni grid (SPI; hole size of 7.6 μm and wire size of 
5 μm) held on the sample with an Al dumbbell-shaped mask.46 The piece of PMMA was 
placed under the UV lamp for 30 min. Next, the PMMA was rinsed with isopropanol 
(IPA) and dried with house nitrogen.  
The UV-modified PMMA sheet was immersed in 0.5 mM N-ethyl-N'-(3-
dimethylaminopropyl)carbodiimide (EDC) + 0.5 mM fluoresceinyl glycine amide 
(Molecular Probes) in pH 7.0, 100 mM phosphate buffer. Then, the immersed PMMA 
was placed on a slow shaker to react overnight. The PMMA sheet was rinsed with pH 7.0 
phosphate buffer and dried by tilting onto a Kim Wipe. Fluorescence images were then 
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immediately taken with a Nikon Photoshot FxA fluorescence microscope. The excitation 















2.2.1.5 DETERMINATION OF SURFACE CARBOXYLATE CONCENTRATION 
As is illustrated in Scheme 2.2, a protocol taken from Pierce Biotechnology, Inc. 
was used to measure the surface coverage of carboxylic acid groups.  
This protocol of course assumes 100% efficiency for each step (amine coupling 
and trityl-carboxylic acid coupling). The procedure can be described as follows: samples 





















      
Scheme 2.1 Chemical mapping of carboxylic acid functionalities with fluoresceinyl 
glycine amide. PMMA was first exposed to UV light through a photomask (2000 
mesh Ni grid, with square holes of 7.6 μm x 7.6 μm). The groups formed as a result 
of exposure were derivatized with fluoresceinyl glycine amide in the presence of 
EDC to produce fluorescence. 
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were prepared by ultrasonication of the PMMA sheets in IPA for 15 min, rinsing with 
IPA, and then drying under house N2 flow. The cleaned PMMA samples were then 
exposed to UV light in the atmosphere for different periods of time, rinsed with IPA, and 
dried under house N2 flow. Each UV-modified PMMA sheet was placed in a capped vial, 
and 2 mL of EDC solution (5 mM in pH 7.0, 0.1 M phosphate buffer) and 30 μL of 





















































Scheme 2.2 Quantification of carboxylic acid groups on UV-modified PMMA 
surfaces using trityl cation method. PMMA sheets were first exposed to UV 
radiation and then the induced functional groups were derivatized with 
ethylenediamine in the presence of EDC to yield an amine-terminated surface. The 
amine-terminated surfaces were then reacted with s-SDTB (sulfo-succinimidyl-4-
O-(4,4’-dimethoxytrityl)-butyrate), and then subsequently exposed to perchloric 
acid to release into solution the trityl cation from the PMMA surface, which 
absorbs strongly at 498 nm. 
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All vials were placed on a shaker table to react for 3 h, after which each sample was 
rinsed thoroughly with 18 MΩ cm water, then placed in a precleaned glass vial 
containing 2 mL of freshly prepared sulfo-succinimidyl-4-O-(4,4’-dimethoxytrityl)-
butyrate (s-SDTB) solution (0.1 mM), and reacted on a shaker for 30 min. (51.4 mL 70% 
perchloric acid + 46.0 mL 18 MΩ cm), and ultrasonicated for 15 min. At this point, each 
sample sheet was rinsed thoroughly with 18 MΩ cm water, placed in a precleaned vial 
containing 2 mL of perchloric acid solution (51.4 mL 70% perchloric acid + 46.0 mL 18 
MΩ cm), and ultrasonicated for 15 min.  The absorbance of the solution in each vial was 
then measured at 498 nm with a Cary 50 UV-Vis spectrometer. 
2.2.1.6 ELECTROOSMOTIC FLOW MEASUREMENTS 
PMMA microchannels (4-cm long × 100-μm tall × 50-μm wide) were formed by 
hot-embossing with the embossing system (vide infra) and the microchannel was 
enclosed by thermal annealing as described above.47 The electroosmotic flow (EOF) was 
measured by the well-established current monitoring method48 described as follows: the 
microchannel and both reservoirs were first filled with a low concentration buffer, one 
reservoir was subsequently emptied and filled with a higher concentration buffer, or vice 
versa. The ionic strengths of the buffers were kept to within 10% of each other (18-20 
mM) so as to minimize double layer compression effects.48 Electrodes were placed in the 
reservoirs, then a high voltage (600 V) was applied across the 4-cm channel, and the 
current was monitored by following—with a multimeter (Fluke 189)—the voltage drop 
across a 10 KΩ resistor connected into the circuit. EOF values were measured using 10.0 
and 20.0 mM acetate buffer in the pH range of 4–6, 10.0 and 20.0 mM phosphate buffer 
in the pH range of 7–8, and 10.0 and 20.0 mM borate buffer in the pH range of 9–10. In 
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these measurements, the voltages from the multimeter were uploaded in real time to a 
computer in which the Flukeview 2.0 program (Fluke) was installed.  
2.2.1.7 ELEMENT-SPECIFIC LABELING OF PMMA SURFACES AND 
ANALYSIS WITH X-RAY PHOTOELECTRON SPECTROSCOPY 
As previously shown49 and is outlined in Scheme 2.3, Tl(OEt) will specifically 
react with carboxylic acid groups while not ester groups, so the amount of Tl coupled to 
the polymer surfaces will indicate the amount of accessible carboxylic acid groups on the 
polymer surfaces.  
Tl(OEt) exposure of pristine PMMA, UV-modified PMMA and poly(methacrylic 
acid), PMAA (Scientific Polymer Products, Inc., Mw = 87,100 and PDI = 1.02) was 
accomplished by placing the polymer spin-coated glass microscope slides in an Ar-filled 
glove box (Vacuum Atmospheres) and covering them with neat Tl(OEt) liquid (Strem 
Chemical, Inc.) for 30 s, rinsing with absolute ethanol, and drying completely. The Tl-
exposed slides were then analyzed with an Axis 165 X-ray Photoelectron Spectrometer 
(Kratos Analytical) using a monochromatized Al Kα (1486.6 eV) X-ray source with a 
power of 150 W. Survey and high-resolution spectra were obtained using pass energies of 
160 eV and 20 eV, respectively. The neutralizer was turned on during the analysis to 
compensate for any possible charge effects on the insulating polymer surfaces. Core level 
binding energies for C1s and O1s were corrected according to Beamson et al. referencing 
the methyl carbons to 285.0 eV and carbonyl oxygens to 532.2 eV, respectively.50  
Curve-fitting of the high-resolution spectra of the Tl-labeled pristine and UV-
modified PMMA was used for mechanistic analysis of the possible photochemical 
reactions described herein. The curve-fitting was performed using a sum of Gaussian-











2.2.2  THEORY OF X-RAY PHOTOELECTRON SPECTROSCOPY (XPS)  
XPS is one type of electron spectroscopy operated under high vacuum with its 
preeminent practical application in surface analysis, namely nondestructive surface 
analysis; it is conventionally also called Electron Spectroscopy for Chemical Analysis 
(ESCA). The principle that is followed to produce surface chemical information is the 
Einstein equation (Equation 2.1). 
Equation 2.1                                 hν = ½ mvc2 + Eb + qФ                                                
Where ν is the frequency of the incoming photon, h is Planck’s constant, ½ mvc2 is the 
kinetic energy of the outgoing electron of mass m and velocity vc, q is a reference charge, 
Ф is the work function of the emitting material, and Eb is the binding energy, which is the 
energy against the Fermi level of the material. As is shown in Figure 2.1, electrons from  
the inner shell of a substrate atom will be ejected and will possess a characteristic binding 
energy if a quantum amount of energy (demonstrated in Equation 2.1) is absorbed upon 
exposure to X-ray source. There are three main types of spectra: survey, high-resolution 











































Scheme 2.3 Tl+ labeling of COOH functionalities on pristine and UV-modified 
PMMA surfaces as was reported by Batich et al.
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parameters in terms of pass energy and energy resolution. In general, 160 eV pass energy 
was used for survey spectra, 20 eV pass energy was adopted for high-resolution spectra, 














The instrumentation setup is shown in Figure 2.2 in which the main components are the 
magnetic and electrostatic lens, hemispherical analyzer and multiple-channel detector.  
For insulating polymer samples, the charge neutralizer is also a very important 
component in the instrument. A monochromatic X-ray source (Al Kα) was used to 
achieve high spatial resolution and acute sensitivity, a neutralizer was adopted to ensure a 
proper surface potential when analyzing insulating samples, and the incidence of X-ray 












Ejected K e- Incoming X-ray
Figure 2.1 Diagram of photoelectron generation from inner shell of sample 
surfaces by X-ray source. 
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maximum intensity of photon flux. The spectrometer was always operated in hybrid 

















2.2.3  THEORY OF FLUORESCENCE51, 52 
 Luminescence is one of the oldest analytical techniques, and it has been 
discovered and applied to various areas for almost five hundred years. Based upon 
different resources of the excitation energy obtained by the luminescent molecules, 
luminescence can be categorized into photoluminescence, chemiluminescence, 
bioluminescence, triboluminescence, cathodoluminescence, and thermoluminescence. 

































Figure 2.2 Schematic layout of the XPS instrumentation. 
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Photoluminescence is generated when luminescent molecules are excited by UV and 
visible photons (refer to the diagram of electromagnetic spectrum in Figure 2.3); it can be 
further divided into fluorescence and phosphorescence according to the paths of energy 










As is illustrated in the typical schematic energy level diagram or Jablonski diagram, 
valence electrons in molecules at electronic ground states (S0) are excited upon 
absorption of a quantum amount of electromagnetic radiation energy (photon) in about 
10-15 second and raised to a singlet excited electronic energy states (Si); there are several 
vibrational levels for each electronic state among which energy dissipation occurs to 
reach the lowest vibrational level, a process named internal conversion. When no more 
excess energy is left in the electron, the electron is now at the lowest vibrational level of 
the first singlet electronic state (S1), and will return to the ground electronic state upon 
emission of energy. This phenomenon is called fluorescence; because there is energy lost 
during the 0.1 second duration of the electron staying at the electronic excited state, the 
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Figure 2.3 Electromagnetic spectrum 
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at the lowest vibrational level of the first excited electronic state (S1) undergoes an 
intersystem crossing or transition from the singlet to the triplet state (T1), 
phosphorescence will occur; the electron at the lowest vibrational level of the triplet state 
















There are mainly three types of fluorescence: Stokes fluorescence, anti-Stokes 
fluorescence and resonance fluorescence. Stokes fluorescence refers to that when 
emission of fluorescence is at a longer wavelength (shorter frequency) or the emitted 
photons are at a lower energy level, and this phenomenon is normally observed in 

















S0 — electronic ground state
Si — singlet excited electronic state




IC — internal conversion
ISC — intersystem crossing
 
Figure 2.4 Jablonski diagram 
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state or if a compound has many highly populated vibrational energy levels, which causes 
the emission to occur at shorter wavelength or longer frequency than that of the 
absorption. This scenario is seen in dilute gases at high temperatures. The third type is 
called resonance fluorescence and occurs when fluorescence photons possess the same 
energy as that of the absorbed photons. It may occur in gases, crystals, and atomic 
fluorescence but never in solution because of interactions between the solvent. 
  Interfering emission of light is also commonly observed during fluorescence 
processes especially at shorter wavelengths of excitation; among these is Rayleigh 
scattering, a phenomenon when an electron is excited to a higher vibrational level instead 
of electronic transition, emits light at the same wavelength as that of the absorbed 
photons within 10-15 seconds, and then returns to the original lower vibrational level. The 
intensity of Rayleigh scattering is inversely proportional to the fourth power of the 
wavelength of the excitation light, so its effect can be minimized by working at a longer 
wavelength. Another form of scattering is called the Raman effect, which appears at 
higher and lower wavelengths (although the former is more common) than the Rayleigh 
scattering peak in fluorescence spectra and are satellites of the Rayleigh scattering peaks 
with constant frequency difference from the exciting radiation. 
  Typical instrumentation associated with fluorescence methods include 
fluorometers and spectrofluorometers, the type used is determined by how the excitation 
and emission signals are selected; in a fluorometer, the excitation and emission signals 
are selected by absorption or interference filters, while in a spectrofluorometer, a 
monochromator is used to select the excitation and emission wavelengths. Shown in 
Figure 2.5 is a typical instrumentation layout of molecular fluorescence, characteristic 












      
 
 
2.2.4 THEORY OF SCANNING PROBE MICROSCOPY (SPM) 
Scanning probe microscopy (SPM) is defined as a family of microscopy forms 
where a sharp probe is scanned across a surface and the interactions between the probe 
and the sample surface are recorded and monitored. It consists of two major types: 
scanning tunneling microscopy (STM) and atomic force microscopy (AFM) (also called 
scanning force microscopy (SFM)). In the work described here, AFM or SFM is the form 
of SPM used for characterizing pristine and/or modified solid substrate surfaces. Atomic 
force microscopy (AFM) was developed in the mid 1980s; it can profile surface features 
and produce three dimensional images with magnifications of up to 1,000,000X. It 
originated from stylus profilers and was advanced in 1986 when Binnig and Quate 
demonstrated an atomic force microscope that can achieve extremely high resolution by 













Figure 2.5 Block diagram for molecular fluorescence spectrometer. 
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There are three operational modes for AFM: contact mode, non-contact mode and 
Tapping Mode. Due to the soft nature of the polymeric materials used for the described 
work here, Tapping Mode AFM is the only choice for surface characterization of the 














As is displayed in Figure 2.6, the major components in a scanning force microscope 
consist of a diode laser which emits 632.8 nm red laser light, a scanning probe (usually 
silicon nitride probes for Tapping Mode SFM) or a force sensor made of an integrated 
assembly of cantilever and tip, a ceramic piezoelectric tube scanner whose geometry 
changes when applying electrical voltages across it, a mirror, and a position-sensitive, 
split-photodiode detector. The sample amounted on the piezoelectric tube scanner is 
moving in the X and Y directions resulting from the electrical voltages applied across the 














Figure 2.6 Schematic of Tapping Mode scanning force microscope. 
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piezoelectric scanner tube. The position changes of the tip by the sample surface is 
sensed by monitoring deflections of the laser light off the backside of the cantilever 
which are directed by the mirror to the detector, a position-sensitive, split-photodiode. 
The forces that occur between the tip and the sample in question in a Tapping Mode SFM 
experiments are mainly Van der Waals forces and columbic forces. Overall, the SFM can 
be simply designated as an electromechanical sensor, in which an electrical change 
(applied voltages) causes mechanical changes in the piezoelectric scanner tube, which is 
further reflected by position changes of the laser on the photodiode detector.     
2.2.5 THEORY OF WATER CONTACT ANGLE MEASUREMENTS 
Water contact angle studies have been used as a quick and qualitative technique 
for characterization of surface wettabilities or surface energies (surface tension); the 
underlying principle can be described by the Young’s equation, Equation 2.2 which 
describes the relationship between the free energy of the interface and a unique contact 
angle θ.  
Equation 2.2                                    γSV – γSL = γLV cosθ                                                
In Young’s equation, γSV refers to the free energy of the interface between solid and vapor 
phases, γSL refers the free energy of the interface between solid and liquid phases, γLV 
refers to the free energy of the interface between liquid and vapor phases, and θ is the 
water contact angle. A typical representative schematic for Young’s equation is 









Figure 2.7 A liquid drop on a solid surface. 
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   Water contact angle goniometry can be used to study unknown substrate surfaces 
by comparison to known reported data, or in the study of modification processes by 
comparison of contact angle values before and after surface modifications. Water contact 
angle measurements include sessile drop static water contact angle measurements and 
dynamic water contact angle measurements. Water contact angle values may qualitatively 
reflect the chemical compositions of a surface, but they are also affected by surface 
roughness, contamination, and water evaporation effects. The volume of water used to 
make the water droplet also plays a role in the outcomes, so it is recommended to 
consistently use the same volume when making water contact angle measurements and 
also make the measurements immediately after the water droplet is formed to avoid any 
possible water evaporation and contaminations.   
2.2.6 THEORY OF ELECTROOSMOTIC FLOW (EOF) 
Electroosmotic flow (EOF) refers to the bulk flow of liquid in a channel; the 
normal flow direction of EOF is defined as that from anode to cathode, while the 
opposite is called reversed EOF. The phenomenon of EOF was first reported as early as 
1809 when Reuss demonstrated in an experiment that water was made to percolate 
through porous clay diaphragms by applying an electric field.54 Electroosmotic flow 
(EOF) has been a crucial factor in many areas especially in the field of chemical and/or 
biological separations when EOF was either an ally by improving separation efficiency 
and providing method of transporting reagents,55 or an enemy by causing band 
broadening in the case of a distorted flow profile induced by variations in the 
conductivity, zeta potential, and viscosity of the fluid.56, 57  
 To fully discuss and understand the origin of EOF, one has to understand one key 
electrical phenomenon, the formation of the electrical double layer (EDL) depicted in a 
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model called the Gouy-Chapman-Stern (GCS) model, as illustrated in Figure 2.9. 
Because no EOF will come into being without formation of an electrical double layer, it 


















When a solid substrate containing a surface charge is in contact with a liquid 
electrolyte, there will form a certain density of net surface charges within a certain 
thickness to the solid substrate plane, and counterions from the solution will adsorb on 
the substrate surface to shield the net surface charges, thus form several layers in the 
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Net negative charges on the glass wall
Figure 2.8 Representation of EOF of a fluid in a glass capillary. 
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solution. The inner layer is relatively immobile, and is called the compact, Helmholtz, or 
Stern layer, which is that between the inner Helmholtz plane (IHP) and the outer 
Helmholtz plane (OHP), while the very outer layer is called the diffuse layer and is 
defined as that between the OHP and the solution reference plane, beyond which is the 













The value of EOF (μeo) is determined by several parameters: the dielectric constant of the 
liquid (ε), the zeta potential of the EDL (ζ), and viscosity of the liquid (η). The 
relationship is defined in Equation 2.3.  
Equation 2.3                                         μeo = − (ε ζ)/η                                                      
It is important to point out that as demonstrated in Figure 2.9, the zeta potential refers to 
the potential in the not-very-well-defined position in the diffuse layer called the shear 
plane.58  























































































Figure 2.9 Schematic of electrical double layer (EDL). 
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2.3  RESULTS AND DISCUSSION 
2.3.1 FLUORESCENCE MICROSCOPIC MAPPING OF CARBOXYLIC ACIDS  
Chemical labeling of carboxylic acid groups on PMMA surfaces followed by their 
examination with fluorescence microscopy was used to identify the presence of 
carboxylic acid groups formed during the photolysis process on the PMMA surfaces. As 
can be seen from Scheme 2.1, fluoresceinyl glycine amide, in the presence of 
carbodimide coupling agent, specifically reacts with carboxylic acids on the PMMA  
 
surface to form amide bonds. This dye has been used previously in mapping carboxylic 
acid sites in acrylate-based polymer microfluidic devices.59 Shown in Figure 2.10 is a 
fluorescence image (λex = 488 nm, λem = 520 nm) of fluoresceinyl glycine amide dye-
labeled PMMA surfaces after being patterned by UV-modification using a 2000 mesh Ni 
grid (hole size of 7.6 μm) mask for 30 min. As outlined in the experimental section, the 
                       
Figure 2.10 Image of photo-patterned PMMA surface; here a 2000 mesh Ni grid 
was used as a mask, exposure time is 30 min. Fluorescence image (λex = 488 nm, 
λem = 520 nm) of specific chemical labeling with fluoresceinyl glycine amide. 
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green squares in Figure 2.10 are where the UV modification was performed and therefore 
the green dye should be present. Control experiments on UV-exposed PMMA without 
EDC did not lead to observation of fluorescence signal. The images obtained from these 
experiments indicate that carboxylic acid groups are formed on UV-modified PMMA 
surfaces using the protocol described here. 
2.3.2   SURFACE TOPOGRAPHIC ANALYSIS OF PRISTINE AND  
UV-MODIFIED PMMA USING SFM  
Surface topography is an important issue for substrate support materials used in 
applications such as biosensors and microanalytical devices, to name a few.32, 60 In 
particular with microfluidic devices, small changes in substrate surface roughness upon 
chemical treatment are desired due to the size of the device features (μm). In this study, 
SFM was used to analyze both pristine and UV-modified PMMA surfaces.  
UV-modified PMMA surfaces are slightly rougher than the pristine PMMA 
surfaces, as can be noted from inspection of Figure 2.11 and Table 2.1. Figure 2.11(A) 
represents a typical 20 μm x 20 μm SFM image of the surface of pristine 0.5-mm-thick 
PMMA sheets (Goodfellow), with the surface being relatively uniform and smooth; the 
RMS surface roughness is 18.0 nm, and the roughness factor, R, is 1.014 (R refers to the 
ratio of the surface cross-sectional distance to the horizontal distance29). Shown in Figure 
2.11(B) is a typical 20 μm x 20 μm SFM image of a 0.5-mm-thick Goodfellow PMMA 
sheet that was UV modified for 30 min under ambient laboratory atmosphere, 
subsequently rinsed with IPA, and then dried with house N2.  
The RMS surface roughness for the 30-min, UV-modified PMMA surface is 27.5 
nm, which is about 50% higher than that of the pristine PMMA, and the roughness factor 
R is 1.067. This increased surface roughness is attributed to photo-induced scission 
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reactions of the polymer chains on the PMMA surfaces.61 Preliminary mass spectrometry 
studies of 1° standard PMMA photochemically modified under the conditions described 
here confirms this scission pathway is operative. However, under the conditions used 
here (15 mW cm-2, t < 2h), the photochemical surface modification route (carboxylic acid 
formation) is dominant, as noted by the relatively small change in roughness values. For 
the longest exposure time, we find an RMS roughness of 32.3 nm and R = 1.094. We 
currently do not understand the origin of the high roughness values for the 10 min 
exposure. All in all, the observed roughness increase upon photochemical surface 



















Figure 2.11 Tapping Mode SFM images of A. pristine PMMA and B. UV-modified 
PMMA (30 min). The scan range for both images is 20 μm x 20 μm, and the Z-range 
is 200 nm. Root mean square (RMS) surface roughness is 18 nm for pristine PMMA 
while 27.5 nm for the UV-modified PMMA. The surface area correcting factor R 














2.3.3 SESSILE-DROP WATER CONTACT ANGLE MEASUREMENTS OF 
PRISTINE AND UV-MODIFIED PMMA SURFACES   
The average contact angle for pristine PMMA surfaces using water as the probe 
was found to be 70o ± 2o (5 replicates), in good agreement with the literature value of 
67°.29, 62 After photochemical surface modification in air, but before IPA rinsing, the 
water contact angle is decreased to about 24° at 30 min exposure time, see Figure 2.12 
When the photochemically modified surfaces were rinsed with IPA, the water contact 
angle values increased, possibly as a result of increased surface roughness caused by IPA 
removal63 of low-molecular-weight polymers61 on the PMMA surfaces formed during the 
photochemical modification process. When PMMA surfaces are exposed to UV light, the 
radical ends resulting from bond breaking events in the irradiated volume can be trapped 
by oxygen in the atmosphere to form initial oxidation products which can undergo further 
Table 2.1 Values of carboxylic acid surface coverage resulting from photochemical 
surface modification of PMMA as a function of modification time (three replicates). 
 
 UV modification time (min) 
 0 5 10 30 60 121 
RMS surface 
roughness (nm) 18.0 14.8 41.1 27.5 33.0 32.3 
Correction factor 
(R) for surface 
area 














0.46±0.01 3.00±2.78 6.61±0.36 13.12±0.53 13.44±0.95 15.53±0.26 
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photolysis to give smaller fragments.61 We hypothesize that the nanoscale roughness 
causes the increase in contact angle in a fashion similar to that recently observed for 



















2.3.4  DETERMINATION OF SURFACE COVERAGE OF CARBOXYLIC ACID 
GROUPS ON PMMA BY VISIBLE DYE LABELING  
UV-Vis spectrometry coupled to carboxylic acid group-specific labeling was used 
to quantify the surface coverage of carboxylic acid functionalities on UV-modified 






















UV exposure time (min)
 Before rinse with IPA
 After rinse with IPA
Figure 2.12 Effects of UV modification on the water contact angle on PMMA 
surfaces. Water contact angle was measured on PMMA surfaces that were UV-
modified in air for different UV exposure times both before rinsing with IPA (solid 
squares) and after rinsing with IPA (solid stars). The water contact angle was 
measured immediately after each treatment to avoid any possible contamination 
from the atmosphere. 
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PMMA surfaces, Scheme 2.2. Before photochemical surface modification, there exist a 
small number of carboxylic acid sites on the pristine PMMA, see Table 2.1 and Figure 
2.13. This is attributed to hydrolysis of the surface PMMA ester groups by either the 
manufacturer production or post-manufacturer production conditions of the polymer 
before its purposeful photochemical modification. The surface concentration of 
carboxylate groups on PMMA surfaces was found to increase consistently with increases 
in the photochemical modification time up to 30 min, and then it tended toward a limiting 
value, as seen in Figure 2.13 The surface coverage of carboxylic acid sites on PMMA 
surfaces reaches 1.68 nmol cm-2 at a modification time of 2 h, which upon correction for 
surface roughness (Table 2.1, R value) is 1.55 nmol cm-2, a value that is ~1.5–2 times that 
of a close-packed alkane monolayer.65 This higher-than-monolayer coverage is most 
likely due to the formation of carboxylic acid groups below the PMMA surface, an 
expected outcome based on the photochemical modification protocol (vide supra). 
2.3.5  EFFECT OF PHOTO-INDUCED CARBOXYLIC ACID PRESENSCE ON 
ELECTROOSMOTIC FLOW IN PMMA MICROCHANNELS  
  Electroosmotic flow has been discussed recently in regards to its magnitude and 
direction for chemically modified PMMA microchannels made through machining29 and 
by laser-ablation.24 To investigate the effect on EOF of carboxylic acid groups resulting 
from photochemical surface modification, a microchannel (100-μm deep, 50-μm wide, 4-
cm long) was hot embossed in PMMA and subsequently irradiated as described here for 
30 min, rinsed with IPA, dried with house N2, and then the microchannel was enclosed 
by thermal bonding in a convection oven with a piece of pristine PMMA cover plate to 


















As is seen in Figure 2.14, the EOF in both pristine and UV-modified PMMA 
microchannels is positive (from anode to cathode) and changes with the pH value of the 
buffer used. For example, the EOF values increased at higher pH for both 
photochemically modified (4.67 x 10-4 cm2V-1s-1 at pH = 9.0 while 1.88 x 10-4 cm2V-1s-1 at 
pH = 4.0) and pristine PMMA microchannels (3.02 x 10-4 cm2V-1s-1 at pH = 9.0 while 
1.72 x 10-4 cm2V-1s-1 at pH = 4.0), and this is attributed to the fact that the accessible 
surface carboxylic acids are deprotonated at high pH and protonated at low pH values. In 
general, the EOF values in photochemically modified PMMA microchannels are higher 
than those in pristine PMMA microchannels, an observation that is consistent with the 
presence of a higher surface density of solution-accessible carboxylic acid moieties. This 































UV modification time (min)
 
Figure 2.13 Surface coverage of carboxylic acids as a function of UV exposure time 
for PMMA surfaces in ambient air. Values uncorrected (solid squares) and corrected 
(solid triangles) for SFM-determined roughness are reported. 
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increased amount of carboxylic acid sites results from the photochemical modification 
process. Thus, the photochemically modified PMMA surfaces possess more ionizable 
functional groups than their pristine counterparts. In addition, the significant change in 
EOF with pH change occurs at a lower pH value for UV-modified PMMA microchannels 
(~pH = 6.0), while this is observed at a higher pH value for pristine PMMA 
microchannels (~pH = 7.0). This observation is most likely related to the issue of surface 
pKa and its dependence on ionizable group surface density, although further work is 
needed to gain a better understanding of this phenomenon. 
2.3.6  MECHANISM FOR THE PHOTOCHEMICAL SURFACE 
MODIFICATION OF PMMA — XPS STUDIES  
As a powerful surface analysis technique, XPS is able to provide information on 
the chemical changes in the very top layer of the PMMA sample where photochemical 
reactions occur.41 The XPS data in Table 2.2 demonstrate that the ratio of O/C on PMMA 
surfaces increases when the UV modification time of PMMA surfaces in air is increased, 
which indicates that introduction of oxygen into the polymer occurs during UV-
modification of PMMA surfaces as described here. This observation is also consistent 
with the results from the chemical labeling (trityl cation, Scheme 2.2) of the carboxylic 
acid functionalities of photochemically modified PMMA surfaces, as it was observed that 
more carboxylic acid sites were formed with increased modification time in Figure 2.13 
To identify the presence of and provide a semi-quantitative evaluation of the 
amount of carboxylic acid sites on the UV-exposed PMMA, we employed a carboxylic 
acid-selective labeling method, Scheme 2.3.49 Thallium ethoxide has been shown to be 
effective for semi-quantitatively labeling carboxylic acids on polymeric surfaces.49 Here, 
neat thallium ethoxide was used to probe the presence of surface carboxylic acid groups 
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on pristine PMMA, UV-modified PMMA and poly(methacrylic acid), PMAA (as a 










































 UV exposure for 30 min
 Pristine PMMA
 
Figure 2.14 Electroosmotic flow measurements in a hot-embossed PMMA microchannel (4 
cm × 100 μm × 50 μm). Plot of EOF vs. pH for pristine (solid triangles) and 30-min UV-
modified PMMA (solid circles). The electroosmotic flow measurements were carried out 
using pH values of 4-10. Three different buffers were used; acetate buffer (pH = 4.0, pH = 
5.0, and pH = 6.0); phosphate buffer (pH = 7.0 and pH 8.0); and borate buffer (pH = 9.0 and 
pH = 10.0). The concentration of buffer was held between 18 mM and 20 mM, while the 
field strength used was 150 V cm-1. For the modified materials, the microchannels of the 

















The Tl/O values were used to obtain approximate carboxylic acid surface 
coverage values upon comparison to a surface that should possess the maximum number 
of carboxylic acid sites, namely, poly(methacrylic acid), PMAA, which we arbitrarily 
assign as a 100% carboxylic acid layer. These surface coverage values are only a rough 
estimate and should not be compared to those from the trityl-labeling route above, for 
they do not reflect the labeling efficiency and the tacticity of the polymeric material used 
(the PMMA is mainly a syndiotactic isomer based on our preliminary NMR results, 
whereas the PMAA possesses a tacticity that is somewhere between isotactic and 
Table 2.2 XPS quantification data of elemental composition of carbon, oxygen and 
the ratio of these two elements in accordance to UV modification time on PMMA 
































syndiotactic), and the depth to which the Tl(EtO) penetrates is possibly different for 
PMAA and PMMA. Furthermore, as pointed out by Batich et al., the method works best 
for surface coverages of carboxylic sites that are less than ~30% of a monolayer.49 As 
noted in Table 2.3, the photochemically modified PMMA surface possesses a much 
higher carboxylic acid surface coverage compared to its pristine counterpart (about 3.5 
times), in general agreement with the trend observed with the trityl-labeling route 








In order to provide insight to the photochemical surface modification mechanism 
– that is identification and quantification of oxygen-containing species possessing 
carboxylic acid functionalities – analysis of the deconvoluted O1s region of the X-ray 
photoelectron spectra for pristine and 30-min UV-modified PMMA surfaces was 
undertaken (Table 2.4 and Figure 2.15). The O1s signal denoted by b in Figure 2.15 
corresponds to the carboxylic oxygen (associated with Tl+ from labeling), that by c the 
O1s for the carbonyl oxygen, and that by a the O1s of the methoxyl oxygen. It is clearly 
seen that the amount of methoxyl oxygen (a) decreased (from 50.2% to 36.1%) while the 
carboxylic oxygen (b) increased (from 3.4% to 19.4%) upon photochemical modification, 
Table 2.3 Comparison of XPS data on different polymer films treated with Tl(OEt). 
           
100 ± 2 0.36 ± 0.021.98 ± 0.11Tl/Standard 
PMAA
39 ± 20.14 ± 0.012.60 ± 0.07Tl/UV-modified 
(30 min) PMMA








indicating that the methoxyl group is cleaved, and the free carboxylic acid is formed 
during UV modification. 
A proposed PMMA photolysis mechanism for the conditions described in this 
report is shown in Scheme 2.4 and is based on others proposed in the literature.67, 68 As is 
illustrated in Scheme 2.4, PMMA is first raised to the excited state upon absorption of 
UV light, and then it can undergo three possible pathways to form different radical 
products. These three pathways may occur simultaneously. In Path I, carbonyl and 
methoxyl radicals are formed, the latter which will extract hydrogen (from water or the 
polymer itself) to yield methanol, while the carbonyl radical will form a peracid in the 
presence of oxygen and UV light, which in turn will lead to carboxyl radicals that react 
with water to yield a polymer-bound carboxylic acid. In Path II, methyl and carboxyl 
radicals are formed, which react with water to yield methane and a polymer-bound 
carboxylic acid. In Path III, tertiary carbon radicals are produced directly from the 
excited state or when the carboxyl radicals in Path II release carbon dioxide. Then, in the 
presence of oxygen, the tertiary carbon radicals may further form alkoxyl radicals 
(through a peroxide intermediate), which in turn lead to polymer chain scission with the 
formation of acetone and alkyl radical on the scissed polymer chain; the latter may 
possibly undergo polymer chain branching reactions.67, 68 It is clear that Path III is 
operative to some degree in the work at hand, as noted by the small increase in PMMA 
surface roughness with exposure time (removal of scission polymer product with IPA 
rinsing) and preliminary mass spectrometry data (vide supra), however it is not the major 
path. Both Path I and II lead to the formation of carboxylic acid sites, but it is currently 
unclear if a given path is dominant. The surface labeling and XPS data support the 
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carboxylic acid formation Paths I and II, but not the specific intermediates. Previous 




















Table 2.4 Comparison of the deconvoluted XPS spectra of pristine and UV-modified 
PMMA. Curve-fitting was achieved by application of a Gaussian-Lorentzian peak 
shape algorithm (70% Gaussian and 30% Lorentzian) after subtraction of a linear 
background. A relative sensitivity factor of 0.780 for oxygen was used in all cases. 
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Figure 2.15 Deconvoluted X-ray photoelectron spectra in the O1s region for 
pristine and 30-min, UV-modified PMMA. A. pristine PMMA after exposure to 
Tl(OEt); B. 30-min UV-modified PMMA after exposure to Tl(OEt). There are 
three components for both spectra, designated as: c. carbonyl oxygen; a. methoxyl 






















2.4  CONCLUSIONS 
This report focused on the surface modification of PMMA with simple UV 
photochemical methods, during which roughly a monolayer of carboxylic functional 
groups is formed. Formation of the carboxylic acids is a relatively surface non-






















































































































































Scheme 2.4 Proposed mechanism for the photochemical surface modification 
reaction under the conditions described here; adapted from previous work. 
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microscopy studies, and is a very important characteristic for applications requiring 
minimal surface damage. The carboxylic acid groups on the PMMA surfaces lead to 
increases in its water wettability and the pH-dependent electroosmotic flow in hot-
embossed microchannels. In addition, the pendant carboxylic groups on PMMA surfaces 
make it possible to further functionalize PMMA-based BioMEMS devices. A possible 
photolysis process mechanism was proposed based on literature reports and outcomes 
from the studies presented here. Polymer-based BioMEMS devices have attracted 
increased interest because of their intrinsic advantages, such as ease of fabricating high-
aspect-ratio features, their low cost, biocompatibility and favorable mechanical 
properties. However, simple and convenient surface modification techniques are needed 
to push these microdevices ahead into the needed applications. The work described here 
provides a new avenue for the “bulk” surface modification of polymer-based BioMEMS 
devices, and more importantly, the spatially controlled modification of polymer surfaces 
that are required for protein and nucleic acid arrays, electronic interconnects, and 
localized fluid control. 
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CHAPTER 3.  PATTERNING ANTIBODIES ON POLY(METHYL 
METHACRYLATE) MICRODEVICE SURFACES 
3.1  INTRODUCTION 
BioMEMS devices have generated significant interest in the analytical 
community, particularly with respect to their applications in biochemical sensing, 
instrument design, and methodology development.1, 2 Compared to their glass- and 
silicon-based counterparts, polymer-based BioMEMS devices offer a broad spectrum of 
substrate materials and fabrication avenues for making the microdevice structures,3, 4 in 
addition to their common intrinsic advantages among microdevices, such as low sample 
consumption, high throughput, and portability.1, 2, 5-8 Several years after the first 
demonstration of miniaturized analytical device fabrication in silicon,9 silicon-based 
miniaturized analytical devices reemerged in 19908 and catalyzed significant 
breakthroughs in device fabrication in glass, such as microseparation devices for 
biologically relevant materials.6, 7 For the most part, the routine wet-chemical etching 
methods used for making silicon- or glass-based analytical microdevices limit the 
industrial scalability of their fabrication and also the formation of high-aspect-ratio 
microstructures due to the isotropic nature of the etching process. Polymer-based 
microdevices are able to address these issues to a significant degree, as there are many 
different types of polymers and fabrication techniques from which to choose, depending 
upon the specific application needs.10-18  
Regardless of the type of substrate materials chosen for fabrication of 
microanalytical devices, an essential objective for further application and utilization of 
these devices is control of the surface properties of the substrate materials via surface 
modification and functionalization through a variety of methods.19 Compared to the well-
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developed siloxane chemistry20 widely used in glass-based microdevices,21 surface 
chemistry for polymer substrates is still being fleshed out.4, 21-29 Well-defined and 
straightforward surface modification protocols are urgently needed for pushing forward 
application of BioMEMS technologies to the field of bioanalysis. For example, once 
amenable surface functional groups on device surfaces are formed, proteins, antibodies, 
enzymes, DNA, and carbohydrates can be further tethered to the modified surface for 
preparation of bio-sensing films using various techniques such as soft lithography, ink-jet 
printing, photolithography, and array printing.30-32 Antibody arrays are among one of the 
growth-area applications, in which antibodies at a certain density are patterned on region-
specific surfaces for parallel and sensitive biospecific analyses.33,34 Integration of 
antibody arrays into microanalytical devices combines the strengths of both techniques, 
which will therefore add further appealing features to these devices such as 
specificity/selectivity, low detection limit, low sample consumption, and fast kinetics.35  
In this work antibodies, specifically anti-human CEA (CEA is a breast cancer 
protein biomarker) antibodies, were immobilized onto carboxylic acid-modified PMMA 
patterns using carbodiimide coupling and protein G chemistries.36 The surface of the 
poly(methyl methacrylate)—a popular thermoplastic polymer used in fabrication of 
microdevices—was first modified through a surface photochemical modification method 
to produce COOH functional groups in a defined pattern.37, 38 Biochemical activities of 
the immobilized anti-CEA antibodies were confirmed to be retained through interactions 
with a secondary antibody or/and a sandwich immunoassay on the surface of planar 
PMMA substrates or PMMA microdevice channels. Surface carboxylic acid patterns 
resulting from the photochemical modification were characterized by scanning probe 
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microscopy (SPM), while attachment of antibodies on UV-modified PMMA surfaces was 
confirmed by elemental analysis in the survey spectra from X-ray photoelectron 
spectroscopy (XPS) studies. Surface ligand densities of the immobilized antibodies, 
either oriented or random, were measured based on a calibration curve constructed by 
near-IR laser-induced fluorescence scanning of standard antibody samples and 
subsequent analysis with a home-built image analysis program.35  
3.2  MATERIALS AND METHODS  
3.2.1  GENERAL 
Poly(methyl methacrylate) sheets, Plexiglass or Lucite, were purchased from 
Goodfellow and were cut to various-sized pieces.  HPLC-grade isopropanol (IPA) and 
other chemicals were obtained from Aldrich and used without any further purification.  
Photochemical modification of poly(methyl methacrylate), PMMA, surfaces to yield 
carboxylic acid functional groups was accomplished by exposure of PMMA pieces to a 
UV light source having a low-pressure mercury lamp possessing an emission spectrum 
spanning the 240 nm to 425 nm range; the 254 nm band is the strongest with an intensity 
of 15 mW cm-2, while that of all others is less than 1.5 mW cm-2 at a 1-cm distance. 
PMMA pieces were first ultrasonicated in IPA for approximately 15 min, rinsed with 
IPA, and then dried with house nitrogen (oil free). The cleaned PMMA was then exposed 
to UV light for 30 min at a distance of 1 cm from the UV lamp, rinsed with IPA, and 
dried with nitrogen. All PBS buffer solutions were prepared in Nanopure water 
(Barnstead, 18 MΩ cm) and were further filtered through MF75 series filter units from 
Nalgene (0.2 μm-pore, surfactant-free cellulose acetate membrane or cellulose nitrate 
membrane). 
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3.2.2  CHARACTERIZATION OF PMMA SURFACES BEFORE AND AFTER 
UV MODIFICATION 
Described here is a typical scanning force microscopy (SFM) topographical 
analysis of PMMA surfaces with patterns resulting from UV modification through a 
contact photo mask. We recently reported a surface photochemical modification protocol 
on PMMA using UV light with the specifications above; characteristics of PMMA 
surfaces before and after UV modification were investigated in aspects of surface 
wettability, surface roughness, surface functionality on plain PMMA sheets, and also 
electroosmotic flows in the PMMA microfluidic conduit.37 As is outlined in Scheme 3.1 
(Step I), a piece of sheet PMMA (2.54 cm × 7.62 cm × 0.05 cm from AIN Plastics) was 
ultrasonicated in 2-propanol (IPA) for 15 min, rinsed with IPA, and dried with house 
nitrogen. The sample was then placed on a microscope slide and a 2000-mesh Ni grid 
(SPI; hole size of 7.6 μm and wire size of 5 μm) held on the sample with a dumbbell-
shaped Al mask. The piece of PMMA was exposed to the UV light for 30 min, then 
rinsed with IPA and dried with house nitrogen. A representative portion of PMMA was 
cut from the UV-modified PMMA piece and then its surface topography was evaluated 
by Tapping Mode SFM. The resulting images were flattened and analyzed using the 
software provided by the SFM instrument manufacturer. 
3.2.3    PATTERNING ANTIBODIES ON UV-MODIFIED PMMA SURFACES 
As is illustrated in Scheme 3.1 (Step II), a primary antibody (Ab1) (Chemicon; 
mouse anti-human CEA monoclonal antibody, clone 1105) was covalently attached to the 
carboxylic acid patterns resulting from UV modification through a contact photo mask 
(SPI; 500 mesh Ni grid with hole size of 39 μm and wire size of 11.4 μm) by 















The procedure can be briefly described as follows: the primary antibody was first 
diluted to a desired concentration (12 μg mL-1) in PBS buffer, N-Ethyl-N'-(3-
dimethylaminopropyl)carbodiimide (EDC, Pierce Biotechnology) was then added to the 
diluted antibody solution so as to give a final concentration of 40 mM. The solution was 
mixed well and immediately sandwiched between two pieces of PMMA with carboxylic 
acid patterns produced in Scheme 3.1 (Step I). The sandwich was placed in a humidified, 
light-proof chamber and incubated at 4 °C for overnight. After incubation, the pieces of 
PMMA were rinsed thoroughly with PBS-Tween200.05% and PBS a minimum of four 
times each to remove possible non-specifically adsorbed antibody molecules from the 
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Scheme 3.1 Approach for patterning antibodies on UV-modified PMMA surfaces and 
the resulting interactions between a dye-conjugated secondary antibody with the 
immobilized primary antibody. 
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any rinsing buffer content and subsequently dried with house nitrogen for surface 
elemental analysis with X-ray Photoelectron Spectroscopy (XPS); for interaction with a 
secondary antibody (Chemicon; goat anti-mouse polyclonal antibody conjugated to FITC 
dye that absorbs at 488 nm and emits at 525 nm, Step III in Scheme 3.1), the pieces of 
PMMA were dried gently either with Kimwipe tissues (blotting) or a slow flow of house 
nitrogen. The secondary antibody (Ab2) was diluted to an intended concentration (12 
μg/mL) in PBS buffer and sandwiched between two pieces of PMMA that had on its 
surface immobilized primary antibody. The sandwich was then incubated at room 
temperature for two hours in darkness in a humidified chamber. The PMMA pieces were 
rinsed again with PBS-Tween 200.05% and PBS thoroughly and blotted dry with a 
Kimwipe or left wet for fluorescence microscopic analysis. A control IgG (bovine IgG 
conjugated with FITC dye, Cortex, 12 μg/mL) was also sandwiched between another two 
pieces of PMMA having immobilized primary antibody on their surfaces, subsequently 
incubated at room temperature for two hours, rinsed with PBS-Tween 200.05% and PBS, 
and imaged with the same fluorescence microscope (Nikon MicroPhot FxA fluorescence 
microscope). All images were analyzed by Leica software to evaluate the pattern 
intensities.  
3.2.4   XPS SURFACE COMPOSITIONAL ANALYSIS OF PRISTINE,  
UV-MODIFIED, Ab1-IMMOBILIZED PMMA 
Pieces of pristine PMMA, UV-modified PMMA, and PMMA modified with the 
primary antibody were placed into the sample transferring chamber (STC) in the X-ray 
photoelectron spectrometer (Axis 165, Kratos Analytical) and the STC then pumped 
down overnight. The samples were then transferred into the sample analyzing chamber 
(SAC) which has an operating vacuum around 10-9 torr. A monochromatized Al Kα 
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(1486.6 eV) X-ray source with a power of 150 W was used for generating X-ray 
photoelectron spectra during the surface analysis; survey and high-resolution spectra 
were obtained using pass energies of 160 eV and 20 eV, respectively. The neutralizer was 
turned on during the analysis to compensate for possible charge effects on the insulating 
polymer surface. Values of core level binding energies for C1s, N1s and O1s were 
corrected for charge effects according to Beamson et al. using the binding energy of C1s 
at 285.0 eV.39  
3.2.5 FABRICATION AND UV-MODIFICATION OF PMMA MICROCHIPS 
BEARING MICROSTRUCTURES IN SIMPLE “T FORMAT” 
The PMMA microfluidic device was fabricated using a method previously 
described.35 In brief, a metal molding die bearing raised microstructures that were 
electroplated from Ni on a stainless steel base plate, was prepared by the X-ray LIGA 
technique. PMMA microstructures were embossed in a system comprised of a PHI 
Precision Press (model number TS-21-H-C (4A)-5; City of Industry, CA) installed with a 
vacuum chamber in order to produce low pressure (<0.1 bar) for complete filling of the 
Ni molding die. During embossing, the molding die was heated to 150 oC and pressed 
into the sheet PMMA at 1000 lb for 4 min. The PMMA part was then cooled to 85 oC for 
demolding. The embossed 0.5-cm thick PMMA microchip bears a simple T format 
microstructure with channel dimensions of 4 cm × 80 μm × 20 μm (referring to channel 
length, depth, and width dimensions). Before any further use, the PMMA microstructured 
device was first rinsed with IPA, ultrasonicated in 2% micro cleaning solution (major 
components include water, glycine and others) for 30 min, rinsed thoroughly with 
Nanopure water (18 MΩ⋅cm), and dried with house nitrogen. The cleaned PMMA 
microchip was then exposed to UV light for 30 min, rinsed with IPA, and dried with 
 91
house nitrogen. The UV-modified PMMA microchip was thermally bonded to a piece of 
pre-cleaned pristine PMMA cover plate (0.05-cm thick) to make the microfluidic conduit 
and was achieved by clamping both parts with glass plates and heating in a convection 
oven at 98 oC for 15 min. It is important to point out that the glass transition temperature 
(Tg) of PMMA (105 oC for pristine PMMA) decreased after UV-modification, so that the 
thermal bonding temperature which is determined by the Tg was also adjusted 
correspondingly.37  
3.2.6 IMMOBILIZATION OF ANTIBODIES ON PMMA MICRODEVICE 
SURFACES  
Immobilization of a primary antibody (anti-CEA monoclonal antibody, mouse 
IgG1, Chemicon, clone 1105) in enclosed microchannels with channel dimensions of 4 
cm × 80 μm × 20 μm (length × depth × width) was carried out by diluting the antibody to 
a specific concentration with PBS (pH 7.40), mixing with 40 mM EDC, and immediately 
adding to the microchannel with a clean disposable plastic syringe. The microdevice with 
antibody solution in the microchannel was then incubated at 4°C for overnight in a 
humidified chamber protected from light. After incubation, the microchannel was rinsed 
with PBS-Tween200.05% using a clean disposable plastic syringe, then with PBS from 
another clean disposable plastic syringe; this was repeated at least four times for each 
step to remove any possibly non-specifically adsorbed primary antibody molecules on the 
PMMA microchannel surface. An FITC-labeled secondary antibody (goat anti-mouse 
polyclonal antibody, Chemicon) was added to the microchannel with a clean disposable 
plastic syringe and then incubated at room temperature in a humidified chamber protected 
from light for two hours. The microchannel was rinsed again with PBS-Tween200.05% and 
PBS, respectively, at least four times for each step to remove any non-specifically 
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adsorbed secondary antibody molecules. The device was kept wet, and the microchannel 
was immediately observed and imaged with a fluorescence microscope (Nikon 
MicroPhot FxA). 
3.2.7 FABRICATION OF A SANDWICH IMMUNOASSAY ON PMMA 
MICRODEVICE SURFACES  
A section of a pre-cleaned PMMA microdevice with dimensions of 4 cm × 100 
μm × 50 μm (channel length × depth × width) was exposed to UV light for 20 min 
through a contact photo mask (750 mesh Ni TEM grid; SPI) held by a quartz plate on top 
of the embossed PMMA microchip. The UV-modified PMMA microchip was then rinsed 
with IPA and dried with house nitrogen. The cleaned PMMA microchip was then 
thermally bonded to a thin sheet of pre-cleaned pristine PMMA (Goodfellow, 0.5-mm 
thick) at 98°C for 15 min in a convection oven. Immobilization of the capture antibody 
(anti-human CEA monoclonal antibody, mouse IgG1, clone 1105; Chemicon) in the 
microchannel was carried out exactly the same way as described in section 3.2.6. It was 
then rinsed in the same manner as in section 3.2.6. and dried gently with a clean 
disposable plastic syringe. Human CEA antigen (Chemicon, 12 μg/mL) was then applied 
to the microchannel with a clean disposable syringe and then incubated at room 
temperature for three hours in a humidified, light-proof chamber. And again the 
microchannel was rinsed the same manner as in section 3.2.6., and dried gently with a 
clean disposable plastic syringe. The detection antibody (mouse anti-human CEA 
monoclonal antibody conjugated with FITC, clone CB-30; Chemicon) was applied into 
the microchannel, and incubated at room temperature for 2 hours in a humidified 
chamber protected from light. After incubation, the channel was rinsed in the same 
manner as in section 3.2.6., left wet and imaged with the same fluorescence microscope. 
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3.2.8 SURFACE LIGAND DENSITY MEASUREMENT WITH NEAR-IR, 
LASER-INDUCED FLUORESCENCE SCANNING MICROSCOPY 
Surface ligand density was measured based on a calibration curve constructed 
with a model antibody (rabbit anti-mouse IgG monoclonal antibody, conjugated with 
IR800 dye; Licor). A series of dilutions of the antibody were made at the concentrations 
of 0, 0.4, 1, 2, and 5 μM in PBS buffer. Then 5 μL of each was spotted on the UV-































≡ Ms anti-human CEA antibody, clone 1105
 
Scheme 3.2 Schematic of a sandwich immunoassay prepared on patterned, UV-
modified PMMA microchannels. The capture antibody is Ms anti-humanCEA 
monoclonal antibody (clone 1105), the antigen is human CEA, and the detection 
antibody is Ms anti-humanCEA monoclonal antibody (clone CB-30) that is conjugated 
to FITC dye. 
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modified PMMA surfaces and scanned by a home-built, near-IR fluorescence scanner 
(excitation at 780 nm, emission at 825 nm) as described in previous work.35 Briefly 
speaking, the scanner is composed of a diode laser (PicoQuant GmbH, model 800, Berlin, 
Germany), counting electronics (PicoQuant GmbH, model SPC 430, Berlin, Germany), 
and single-photon avalanche diode (SPAD, EG&G Optoelectronics, model SPCM-PQ, 
Vaudreuil, Canada). The microscope has a 40x objective (Nikon, Natick, MA) and a high 
numerical aperture (NA = 0.85). The fluorescence images were achieved by scanning the 
sample attached to a microtranslational stage which was controlled by step motors. The 
step resolution of the acquired fluorescence images was 101.6 μm and the integration 
period was at 100 ms. Fluorescence images were obtained and analyzed using a home-
built program called HarpPlayer, in which fluorescence intensity of each pixel on the 
image was recorded during fluorescence scanning of the standard fluorescence spots. To 
be consistent, fluorescence intensity values reported here for each concentration used for 
construction of the calibration curve was an average of intensities from seven 
representative pixels within the fluorescent spot; background subtraction was achieved by 
using the average fluorescence intensity from the 0-nM antibody spot.  
Direct or random immobilization of the antibody was carried out with the same 
procedure described in section 3.2.3. or 3.2.6., while oriented immobilization was 
accomplished using protein G, a Fc receptor of the antibody. Protein G was first 
immobilized using the same procedure as that of antibodies; bovine serum albumin 
(BSA) was used as a blocking agent, and then the antibody was spotted on a protein G-
immobilized area and incubated at room temperature for two hours in a humidified 
chamber that was protected from light. Afterwards, all rinsing steps were the same as that 
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in section 3.2.3. Both devices were imaged immediately after preparation to avoid any 
possible quenching.  
3.3  RESULTS AND DISCUSSION   
3.3.1  SFM SURFACE TOPOGRAPHY ANALYSIS OF CARBOXYLIC ACID 
PATTERNS RESULTING FROM UV-MODIFICATION OF PMMA 
In general, UV-modified PMMA surfaces are rougher than pristine PMMA 
surfaces. Shown in Figure 3.1 is an SFM image of a patterned, 30-minute UV-modified 
PMMA surface and the corresponding cross-section. In Figure 3.1(A), areas that are 
darker in color (UV light transmitted area) are physically lower in height than those areas 
that are lighter in color (UV light blocked area); the cross-sectional analysis in Figure 
3.1(B) demonstrates the depth difference between pristine PMMA surfaces and UV-
modified PMMA surfaces to be less than approximately 90 nm. This height difference 
indicates that material is removed from the polymer surface during the UV-induced 
formation of COOH functional groups. As we have shown previously, this damage can 
be minimized by using shorter exposure times that still yield sufficient carboxylic acid 
functional group density.37, 38 Importantly, the surface damage incurred during the surface 
modification protocol is negligible in comparison to the dimensions of built-in 
micrometer-scale features of microfluidic devices. We have used longer exposure times 
here to produce patterns that are readily observable by SFM.  
3.3.2  CONFIRMATION OF ANTIBODY IMMOBILIZATION ON COOH-
MODIFIED PMMA SURFACES USING XPS AND FLUORESCENCE 
MICROSCOPY 
XPS is a powerful surface analysis tool for monitoring compositional changes on 
surfaces resulting from chemical reactions. Pristine PMMA, UV-modified PMMA and  
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Figure 3.1 A. Tapping mode SFM image of sheet PMMA that was UV modified 
through a photomask (2000 mesh Ni TEM grid, with square holes of 7.6 μm × 7.6 μm); 
and B. Cross-sectional analysis of the patterned image in A. Point a in the image and 
line trace denotes where there is no UV-modification, while point b points to where 
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Figure 3.2 Confirmation of the immobilization of antibody molecules on UV-
modified PMMA surfaces by X-ray Photoelectron Spectroscopy. Shown are XPS 
survey spectra of: A. antibody-immobilized PMMA; B. 30-min, UV-modified 
PMMA; and C. pristine PMMA. There are only two components in the spectra for 
both pristine and UV-modified PMMA surfaces, namely carbon and oxygen, while 
there is an additional nitrogen peak in spectrum C indicating the immobilization of 
antibody molecules. 
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primary antibody (Ab1)-modified PMMA were evaluated with XPS to compare the 
surface compositional changes at each step of functionalization. As is shown in the 
survey spectra in Figure 3.2, there are only two elemental components in both pristine 
and UV-modified PMMA, namely carbon and oxygen; the C/O ratio is different as a 
result of the presence of carboxylic acid groups for the UV-modified PMMA. In the 
spectra of the antibody-immobilized PMMA surfaces, the signal for nitrogen at 399.8 eV 
is clearly evident and indicates the successful biofunctionalization of the UV-modified 
PMMA surface by direct linkage of the amine residues of the CEA antibody to the 
carboxylic acid groups of the COOH-PMMA. XPS cannot provide any information on 
the biochemical activity of the immobilized primary antibody, so we turned to 
fluorescence microscopy.  
Shown in Figure 3.3 (Upper) is a fluorescence microscopic image of a patterned 
Ab1-PMMA surface, which was obtained as outlined in Scheme 3.1. Briefly, this was 
achieved by carbodiimide immobilization of primary antibody (Ab1) on a COOH-
patterned PMMA surface, followed by exposure to a secondary antibody (Ab2) that is 
specific for Ab1 and is conjugated with a green fluorescence dye (FITC). The bright 
green squares in Figure 3.3 (Upper) are where the secondary antibody was introduced and 
corresponds to where the UV-modification occurred so as to produce COOH functional 
groups capable of forming amide bonds during the carbodiimide coupling. The control 
image in Figure 3.3 (Lower) is used to determine the possible existence of non-specific 
interaction events between the secondary antibody and the primary antibody; the 
patterned Ab1-PMMA surfaces were exposed to solutions of bovine IgG that should not 
interact with the primary antibody. The images were analyzed using fluorescence 
 99
microscopic imaging software LCS (Lica), and the signal-to-noise ratio (SNR, defined as 
(signal – background)/(background)1/2) in the image in Figure 3.3 (Upper) is seven times 
higher than that of the control in Figure 3.3 (Lower). In summary, the fluorescence 
images support the conclusion that the immobilized primary antibody is not denatured 
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Figure 3.3 Fluorescence microscopy is used to investigate the biochemical activity 
of the primary antibody (mouse anti-human CEA IgG antibody) immobilized after 
patterned UV modification. A secondary antibody (goat anti-mouse IgG) that is 
conjugated to FITC dye was introduced to interact with the immobilized primary 
antibody. A non-specific IgG molecule (bovine IgG) that is conjugated to FITC was 
used as a negative control to address the non-specific interaction issue.  
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3.3.3  BIOFUNCTIONALIZATION OF THE SURFACE OF PMMA 
MICROFLUIDIC DEVICE FEATURES AND CHARACTERIZATION OF 
ANTIBODY ACTIVITY  
In order to investigate the effects of microfluidic device feature nature (planar 
surface versus channel structure) on the immobilization of antibodies, the methods in 
Scheme 3.1 and 3.2 were used for hot-embossed PMMA channels of 80 μm depth, and 20 
μm in width. First, the impact of immobilization of the anti-CEA antibody in the 
microchannel was investigated. Upon following the protocol in Scheme 3.1 and 
subsequent fluorescence microscopy examination of the PMMA microchannel, it was 
found that the immobilized Ms anti-CEA antibody was recognized by the FITC-labeled 
goat anti-mouse antibody, see Figure 3.4(A), indicating that as in the case of the planar 















Figure 3.4 Biofunctionalization of microfluidic channel surfaces and fluorescence 
microscopic evaluation of biochemical activity of the immobilized mouse (Ms) anti-
human CEA antibody through: A. interaction with a secondary antibody (goat anti-Ms 
polyclonal antibody) that is conjugated to FITC dye; and B. a sandwich immunoassay 
wherein CEA is captured by the immobilized Ms anti-human CEA antibody and then 
reported using the FITC-labeled Ms anti-human CEA antibody. Channel dimensions 
in A are 80 μm depth × 20 μm width and 100 μm depth × 50 μm width in B. Device is 
fully functional in B (sealed channel with PMMA cover plate). 
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Depicted in Scheme 3.2 is the sandwich immunoassay protocol which involves 
immobilizing anti-CEA antibodies on COOH-modified PMMA surfaces at 4°C 
overnight, then capturing the antigen CEA by incubating at room temperature for 3 h, and 
the CEA capture event being detected through another anti-CEA antibody that is labeled 
with FITC. Patterned fluorescence signal was observed in the PMMA microchannel 
(depth is 100 μm and width is 50 μm) that has undergone the sandwich immunoassay 
procedure as shown in Figure 3.4(B). Within the microchannel, there are green 
fluorescence stripes that are around 25 μm long which correlates to the hole size of the 
patterning mask, the 750 mesh Ni grid, and this therefore indicates that the primary anti-
CEA antibodies were immobilized on the location where COOH functional groups were 
produced through UV modification, CEA antigen was subsequently captured and 
detected by another different clone anti-CEA antibodies that are pre-labeled with FITC 
dye. 
3.3.4  MEASUREMENT OF SURFACE LIGAND DENSITY USING NEAR-IR 
DYE LABELED IgG ANTIBODY  
  A calibration curve was constructed using the average fluorescence intensity 
obtained from spots of dried antibody solutions possessing different IgG concentrations. 
Examination of the spots on PMMA substrates using a scanning microscope capable of 
imaging the NIR dye-labeled IgG and subsequent integration of spot intensity with 
HarpPlayer software leads to the plot in Figure 3.5, which demonstrates the linear 
relationship between the amount of fluorescently-labeled IgG antibody present and the 
fluorescent signal. This calibration curve was used to determine the surface density of 
randomly immobilized and oriented IgG antibodies on PMMA. The surface density of 
randomly immobilized IgG antibodies is 0.38±0.02 pmol cm-2, while that for the IgG 
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immobilized using a protein G layer is 0.21±0.01 pmol cm-2, both of which are lower 
than the theoretical value for one monolayer of IgG molecules. A monolayer of IgG 
assuming a flat arrangement of the protein on the surface is 1.1 pmol cm-2.40 The lower-
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Figure 3.5 Determination of surface antibody density using near-IR, laser-induced 
fluorescence scanning microscopy. A model antibody that is conjugated to an 800-nm 
emitting near-IR dye is used to construct the calibration curve. The intensity values 
reported are the average of seven representative pixels within the same fluorescent spot; 
error values are ± one standard deviation. Surface ligand densities of random and oriented 
immobilization of antibodies were both determined using the calibration curve.  
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3.4  CONCLUSIONS  
  Antibodies specific for carcinoembryonic antigen (CEA), a breast cancer 
biomarker, have been successfully patterned on poly(methyl methacrylate)-based 
microanalytical device surfaces. The patterning method is very simple and 
straightforward and combines carbodiimide coupling chemistry with the direct, spatially-
selective formation of carboxylic acid groups induced by exposure to UV light through a 
contact mask. Retention of the biochemical activity of the patterned, polymer-bound 
antibodies was confirmed, and surface ligand density measurements of immobilized 
antibodies yielded values characteristic of a submonolayer of antibody, with the surface 
density being 80% larger for randomly immobilized antibodies in comparison to their 
protein-G oriented counterparts. Considering the fact that there is a large interest in 
developing disposable, polymer-based microdevices for potential applications in 
biomedical and clinical diagnosis of diseases that will require the use of immunological 
recognition agents in array-based formats, the work reported herein sheds some light on 
promising methods for the patterned immobilization of biologicals that are simple to 
utilize. 
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CHAPTER 4.  PREPARATION OF BREAST CANCER GENE BIOMARKER BRCA1 
MUTATIONAL MATERIALS   
4.1 INTRODUCTION 
4.1.1  BRCA1 AS THE TARGET GENE FOR DIAGNOSIS OF BREAST CANCER 
SUSCEPTIBILITY 
Breast cancer is one of the most common and fatal cancer diseases that affects women 
worldwide (Breast Cancer Information Core (BIC), http://research.nhgri.nih.gov/projects/bic/). 
As is true with most other cancer diseases, early detection of breast cancer is very crucial for 
proper medical treatment because treatment of advanced breast cancer will be much more 
difficult and inconsistent, often futile and disfiguring.1  
 Around 10% of breast cancers are caused by inherited genetic mutations (or abnormal 
genetic sequences), among which are mutations in the two most commonly involved genes, 
namely Breast Cancer Type I Gene (BRCA1) and Breast Cancer Type II Gene (BRCA2), with a 
higher risk with BRCA1 abnormalities. People who inherit mutations in this gene will have a 
higher risk of developing breast cancer (50-85% chance of developing breast cancer in the 
lifetime2) as well as types such as ovarian cancer. The BRCA1 gene, which expresses a specific 
protein in breast and ovarian tissue, has been found to be a DNA damage repair and tumor 
suppressor gene,3 meaning that at its normal stage, it maintains normal cell growth of breast 
tissue and suppresses tumor formation through the process of protein expression. Since it was 
initially mapped to chromosome arm 17q in the early 90s,4, 5 considerable efforts have been 
devoted to BRCA1 research, including development of reliable, inexpensive, accurate, and 
sensitive testing methods, either by a combination of PCR amplification and 2-D electrophoresis6 
or by using fluorescence-assisted mismatch analysis for screening.7 Despite the existing 
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techniques available to research and clinical implementations, there is still an urgent need to 





















4.1.2  CELL LINES AS EFFECTIVE BREAST CANCER STUDY MODEL SYSTEMS   
Cell lines can be established such that they preserve the similar properties to that of the 
tumor from which they were derived. Furthermore, cell lines derived from either primary or 
metastatic cancers can provide unlimited sources of cells that can further be distributed to help 
comparative studies among different labs. Specifically, for breast cancer cell lines, there are 







Figure 4.1 Homo sapiens genome view and the location of BRCA1 gene in chromosome 17. 
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available and widely studied breast cancer cell lines are metastatic cell lines, such as MCF-7 
breast cancer cell lines. In order to develop effective techniques for early detection of breast 
cancer, primary breast cancer cell lines are required. In the reported work, HCC1937 (Hamon 
Cancer Center), a primary breast cancer cell line that was established at Southwestern Medical 
Center and deposited at American Tissue Culture Center (ATCC) by Gazdar and coworkers,8, 9 
was used as a tumor model system from which the genomic BRCA1 gene was isolated and 
further analyzed via PCR/LDR combined assays. A primary colon carcinoma cell line (HT-29, 
ATCC) was used as a wild-type control for the breast cancer cell line (HCC1937). 
4.1.3  POLYMERASE CHAIN REACTION (PCR)/LIGASE DETECTION REACTION 
(LDR) COMBINED ASSAYS  
Polymerase chain reaction (PCR) was first discovered by Kary Mullis and his colleagues 
at Cetus Corporation in the early 1980s.10 Combined with the breakthrough of isolation and 
purification of a thermal stable polymerase11 and the birth of programmable thermal cyclers, 
PCR has since dramatically reshaped the structure of experimental molecular biology, providing 
researchers with a superior tool that combines high sensitivity and specificity with great 
flexibility. It is not surprising that Kary Mullis was therefore awarded the 1993 Nobel Prize in 
Chemistry less than ten years after the invention of the PCR technique. 
Since its discovery, there have appeared dozens of versions of PCR reactions, such as 
real-time PCR and reverse-transcriptional PCR. A typical PCR reaction involves gently mixing 
all the necessary reaction components, performing the amplification reaction in a thermal cycler, 
and testing the fidelity of the PCR product. The PCR components are of water, reaction buffer, 
MgCl2, dNTPs, forward primer, reverse primer, target DNA, and polymerase, each of the 
components needing to be chosen and designed carefully. Normally, the water used in the PCR 
reaction is deionized and sterilized and is commercially available. The PCR buffer is intended to 
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provide optimal pH and monovalent salt environment for the final reaction; commercial PCR 
buffer (pH 8.4) is usually a 10X concentrated solution which includes 200 mM Tris-HCl, 500 
mM KCl, and 15 mM MgCl2 (cofactor for the polymerase). The final concentration of MgCl2 in 
the PCR reaction can also be further adjusted to obtain optimum result. 
Deoxynucleotides (dNTPs) are added as the bricks for the PCR product, the doubly 
stranded DNA. Moreover, they provide energy for the reaction because the β and γ phosphates in 
the dNTPs are the only energy source among all the reaction components. The amount of DNA 
template used in the cycling is somehow dependent on how much DNA is available and how 
easy it is to replace it; it should also be free from contaminants, such as other DNA sources. The 
key player that contributes to the automation of PCR is the thermally stable enzyme or the DNA 
polymerase that can actually function at high temperature and beyond. There are several 
commonly used DNA polymerases, including the “gold standard” used in PCR, Taq DNA 
polymerase which was initially isolated from Thermus aquaticus from the outflows of the 
thermal pools of Yellowstone National Park. Other thermally stable polymerases isolated from 
other thermophilic bacteria consist of Pfu, Tth, Tfl, Tli, and others.  
Each of these thermally stable polymerases possesses specific attributes in terms of 
processivity, fidelity, and persistence, and their choice in a given amplification is based on these 
attributes. Most of the aforementioned components can be ordered from commercial sources and 
used as is except the DNA template. Particular efforts are mostly invested in the designing of 
PCR primers and optimizing the annealing temperature in order to acquire the optimal PCR 
amplicon. As is depicted in Figure 4.2, a typical PCR thermal cycling comprises three steps: 
denaturing the DNA template at 94°C, annealing at appropriate temperature, and extending the 
strand at 72°C.  
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Figure 4.2 Schematic of Polymerase Chain Reaction (PCR) 
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Automatic PCR has been a powerful tool in the molecular biology field, while another 
automatic thermal cycling process called the ligase detection reaction (LDR) has further 
revolutionized DNA diagnostics. LDR has evidenced in discrimination of single-base difference 
between the wild type and the mutated type genetic materials since it was invented by Barany 
and coworkers.12 LDR itself is able to amplify DNA templates in a proportional manner, but it 
can be raised to an exponential amplification scale if it is coupled with another set of adjacent 
oligonucleotides, complementary to the first set and the target. Shown in Figure 4.3 is schematic 













In LDR, the cloned thermally stable enzyme or LDR ligase specifically links two 
adjacent oligonucleotides when they are hybridized at 65°C to a complementary target and only 


























Figure 4.3 Schematic of Ligase Detection Reaction (LDR). 
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thermal cycling process is composed of three steps: denaturing the double-stranded DNA 
template at 94°C, the specific ligation at 65°C, and last linear amplification at 65°C. 
The LDR reaction mechanism involves the formation of a phosphodiester bond between a 
3'-hydroxyl group from one of the two primers, namely the discriminating primer, with the 
phosphate group on the 5' end of another primer called the common primer. The key molecular 
driving force for the reaction comes from a very specific ligation enzyme while the energy 
source is from the enzyme cofactor nicotinamide adenine dinucleotide (NAD+) for this 
thermodynamic reaction. 
When PCR is coupled to LDR, the exquisite specificity inherent in LDR will make 
multiplexing possible as different primer sets are able to simultaneously ligate along the same 
DNA template without the interference commonly seen in PCR-based assays.13-15 It will further 
increase the throughput of the assay when DNA arrays (gene chip), which normally utilize 
hybridization events between the immobilized probe and the targeting sequence, are incorporated 
into the multiplexed assay. Thanks to the series of efforts invested by Barany and related 
laboratories, the Zipcode universal DNA array format has been further increasing the sensitivity 
and detection limit of the multiplexed assay due to the fact that the universal array format 
uncouples mutation detection from array hybridization and, therefore, is capable of detecting 
frame shift, deletions and single point mutation16 that are not always achievable during direct 
hybridization.17         
4.1.4 SLAB-GEL ELECTROPHORESIS (SGE) 
New technologies such as capillary-gel electrophoresis and microdevice electrophoresis 
have emerged in recent years and have played important roles in biomacromolecule analysis. 
Due to the fact that traditional slab-gel separations offer high parallel profiling and easy 
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accessibility, SGE has not been completely replaced and is still commonly used in most 
biological research labs for biomacromolecule separations for assessment of impurities and 
identification of unknown compositions. 
There are two types of slab-gel electrophoresis: agarose gel electrophoresis and 
polyacrylamide gel electrophoresis. Agarose gel electrophoresis is mainly employed to separate 
nucleic acid molecules or very large proteins. The gel is made of agarose, a compound derived 
from seaweed, which is made of a linear polysaccharide of galactose and 3,6-anhydrogalactose. 
The commonly used concentrations of agarose gel include 0.8%, 1.0%, and 3.0% (the percentage 
of agarose in the buffer added during casting) and they are able to separate nucleic acids ranging 
from 20bp to 20,000bp.  
Poly(acrylamide) gel electrophoresis is widely used for separation of protein and small 
nucleic acid molecules. Poly(acrylamide) is a polymer made of the monomer acrylamide and 
crosslinker such as bis(anylamide). Depending upon the proportion of crosslinker added during 
polymerization, there will form different pore-sized poly(acrylamide) gels. Poly(acrylamide) gel 
electrophoresis can be categorized into native or non-denaturing poly(acrylamide) gel 
electrophoresis (PAGE) and denaturing poly(acrylamide) gel electrophoresis or sodium dodecyl 
sulfate-poly(acrylamide) gel electrophoresis (SDS-PAGE). Sodium dodecyl sulfate is the only 
component difference between PAGE and SDS-PAGE.  
PAGE is employed when the activity of biomacromolecules needs to be retained during 
separation, while in SDS-PAGE, the strong ionic detergent SDS denatures secondary, tertiary, 
and quaternary structures by binding to hydrophobic regions of protein, and its binding also 
confers net negative charges on the protein, which results in a constant charge-to-mass ratio. 
Therefore, the proteins are separated on the gel in the electrical field by their mass. Buffer 
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systems used in protein separation with poly(acrylamide) gel electrophoresis include sample 
buffer and running buffer; the commonly used sample buffer for SDS-PAGE is Laemmli buffer 
named after the researcher who invented the buffer system (pH 6.8), which comprises 62.5 mM 
Tris-HCl, 2% SDS, 25% glycerol, and 0.01% bromophenol blue. In PAGE for large-molecular-
weight protein separation, the sample buffer (pH 6.8) typically consists of 62.5 mM Tris-HCl, 
40% glycerol, and 0.01% bromophenol blue. For peptide and small protein denaturing gel 
separation, the sample buffer (pH 6.8) consists of 200 mM Tris-HCl, 2% SDS, 40% glycerol, and 
0.04% coomassie blue G-250. Components in the running buffer (pH 8.3) for protein denaturing 
slab gel separation can be either 2.5 mM Tris, 19.2 mM glycine, and 0.01% SDS for large 
proteins, or 10 mM Tris, 10 mM Tricine, and 0.01% SDS for peptides and small proteins.      
 As is true with protein separations, there are also different buffer systems for nucleic acid 
separations depending upon specific applications of the electrophoresis using either agarose or 
poly(acrylamide) gels. There are two types of sample buffers: TBE-urea (pH 8.0) buffer and 
TBE (pH 8.0) buffer. The former is used for denaturing ssDNA and RNA separations and 
consists of 89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA, 7 M urea, 12% Ficoll, 0.01% 
bromophenol blue, and 0.02% xylene cyanol FF. The latter is used for nondenaturing and 
dsDNA separations and comprises 50 mM Tris-HCl, 25% glycerol, 5 mM EDTA, 0.2% 
bromophenol blue, and 0.2% xylene cyanol FF. The running buffer typically used for nucleic 
acid electrophoresis is either TBE or TAE buffer; TAE buffer offers faster electrophoresis but 
lower resolutions than TBE buffer.  
 The electrophoresis system can be set up to run either vertically or horizontally. 
Biomacromolecules (proteins or nucleic acids) always migrate from the cathode (-) to anode (+) 
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in the electrical field. Representative electrophoresis setups (Bio-rad), including both horizontal 















      
 
On the slab gel, biomacromolecules can be either qualitatively identified by comparison 
with a well-defined step ladder, or quantitatively measured by using a precision sizing standard 
run on the same gel as the target sample, an imaging device, and some image analysis software, 
such as ImageQuant. Once identified or quantified, target samples in the gel can be further 
purified by cutting the specific band out of the gel and then subsequently treatmenting it using 
    







     
 
Figure 4.4 Typical slab gel electrophoresis experimental setups and results. At upper left is a 
typical vertical electrophoresis setup for ready gel precast gel electrophoresis, while at lower 
left is a typical horizontal setup for ready gel precast gel electrophoresis (Bio-Rad). On the 
right is a schematic of a working slab gel with eight wells where samples and sizing standard 
are injected.  
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chemical methods (dissolving the gel and extracting the product) or others (e.g. freeze & 
squeeze) to expel the pure target product out of the slab gel.  
4.2     MATERIALS AND METHODS  
4.2.1 GENERAL  
Illustrated in Figure 4.5 is an overview of the strategy used for analysis of BRCA1 gene 
isolated from a primary breast cancer cell line; a PCR/LDR multiplexed assay is adopted to 




















The breast cancer cell line (HCC1937) used in the assay was purchased from American 











































Figure 4.5 The adapted PCR/LDR combined assay for detection of single insertion mutation in 
the BRCA1 gene. 
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deposited by Gazdar and coworkers from University of Texas Southwestern Medical Center, 
bears a single insertion C at position 5382 in exon 20 of the germ-line BRCA1 gene.8, 9 The cell 
line was further cultured using the protocol provided by ATCC. Culture reagents include cell 
culture medium (RPMI 1640 medium, Sigma), 10% fetal bovine serum, and 1:500 of 
antibiotic/growth medium. Major facilities include a liquid nitrogen tank for storage of the cell 
line, a laminar-flow hood equipped with UV lamp for dealing with the cell line, microanalytical 
centrifuges, water bath, and incubation oven (37ºC, 5% CO2).  
Isolation of genomic DNA from the cultured cells was accomplished with a kit from 
Sigma (Genelute Mammalian Genomic DNA Kit). The PCR amplification kit was ordered from 
Promega, while the primers were customer synthesized product from Integrated DNA 
Technologies (IDT). The LDR reaction kit, including the reaction buffer and ligase, was 
purchased from New England Biolabs (NEB). The discriminating and common primers were 
customer synthesized product from IDT, and the water used is nanopure water produced in the 
research lab. The agarose gel electrophoresis setup (Bio-Rad) is a horizontal setup specifically 
designed for ready gel precast mini-gels, while that for the polyacrylamide gel electrophoresis of 
the LDR product is connected to a 700-nm near-IR detector (Licor). All the slab gels, including 
agarose gels and polyacrylamide gels, are ready gel precast mini-gels purchased from Bio-Rad 
Corporation. All the buffers, either running buffer or sample buffer, are from Bio-Rad. The 
staining agent, or the DNA intercalating dye ethidium bromide (EtBr), is also from Bio-Rad. The 
25bp DNA step ladder was purchased from Promega, while the 50-350bp concentrated sizing 
standard used in the analysis of LDR product fidelity is a product of Licor Biosciences and is 
composed of 14 IRDye700-labeled DNA fragments with equal banding intensities in 90% 
formamide solution with bromophenol blue. Procedures of using this near-IR sizing ladder are as 
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follows: denaturing the solution at 95ºC for 1-2 min, placing on ice for 10 min, and then loading 
0.2 μL for any well or comb. The imaging system for either agarose gels or poly(acrylamide) 
gels is a Kodak imaging system equipped with epi-white light and UV transmission light. 
Analysis of gel images was done with imaging software such as ImageQuant.  
4.2.2  CELL CULTURE OF PRIMARY BREAST CANCER CELL LINE  
The procedure for the cell culture can be described briefly as follows: first of all, a 
sufficient amount of cell growth medium (100 mL in total) was prepared, which includes 10 mL 
of fetal bovine serum, 0.2 mL antibiotic, and 90 mL RPMI1640 medium (2 mM L-glutamine, 1.5 
gL-1 sodium bicarbonate, 4.5 gL-1 glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate). The 
growth medium was then sterilized by passing through a filter unit (150 mL PES filter unit with 
0.22 μm size pore, Corning Inc.) using a sterile syringe. Next, the cell line was added to a 
centrifuge tube, 12 mL of the prepared growth medium was pipetted into the tube and mixed 
with a sterile syringe. 4 mL of the cell line in the growth medium was added to each of the three 
p60 petridishes which have a bottom surface area of 25 cm2. The cells were observed under a 
microscope to ensure the proper density of the cells, and then placed in the incubation oven (37 
ºC, 5% CO2). Finally, a daily check on the cell growth was performed in order to make sure the 
cells were growing normally. The medium was also changed.  
When the cell line grew to a good degree of confluency, it was ready for splitting. The 
old growth medium was removed with a sterilized disposable syringe by gentle vacuuming, then 
1-mL of trypsin was added to the petridish to detach the cells from the bottom surface, then cells 
removed with a sterilized disposable syringe by gentle vacuuming, and then another 1 mL of 
trypsin was added to the same petridish and incubated in the incubation oven for 2-5 min to help 
achieve complete detaching.  
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For splitting the cells, 8-mL of the growth medium (already warmed in a 37 ºC water 
bath) was added to the p60 petridish and mixed well with a sterilized pippet three times, and the 
9 mL of the cell suspension (1 ml of the added trypsin plus 8 mL of the added growth medium) 
was evenly split into three new p60 petridishes and mixed thoroughly by a set of shakings. The 
split cells can be further cultured in the incubation oven or used for other application.  
4.2.3  ISOLATION OF GENOMIC DNA FROM THE CULTURED CELLS 
   The isolation of genomic DNA from the cultured cells was carried out with an isolation 
kit from Sigma as is depicted in Figure 4.6.18 Generally, the procedure is as follows: the cells 
were first harvested by detaching them from the petridish bottom surface with trypsin, 5 mL of 
the growth medium was then added, and the detached cells were transferred to a plastic tube. The 
cells were then pelleted at 300 x g for 5 min and the growth medium was carefully removed with 
a wide-pore pipette tip. The cell pellet was resuspended thoroughly in 200 μL of the resuspension 
solution, 20 μL of the proteinase K solution and 200 μL of lysis solution C were then added. The 
new cell suspension was then agitated on a vortex mixer for about 15 sec and incubated at 70 ºC 
for 10 min. 500 μL of the column preparation solution was added to each pre-assembled 
GenElute Miniprep binding column and centrifuged at 13,000 x g for one min. Finally, 200 μL of 
absolute ethanol was added to the lysate and mixed well by agitation on the vortex; the lysate 
was then transferred with a wide-pore pipette tip (100-1000 μL) to the pretreated binding column 
and centrifuged at 7,300 x g for one min. The flow-through liquid was discarded and the binding 
column was now placed in a new 2 mL collection tube. 500 μL of pre-diluted washing solution 
was added to the binding column, and the column was centrifuged at 7,300 x g for one min. A 
second wash can be carried out with the same washing solution. At last, 200 μL of the elution 
solution was added directly to the center of the binding column, incubated at room temperature 
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for five min, and centrifuged at 7,300 x g for one min to elute the genomic DNA. A second 
















4.2.4  POLYMERASE CHAIN REACTION (PCR) AND OPTIMIZATION OF THE 
REACTION CONDITIONS  
The genomic sequence of exon 20 (68917-69000) from Homo Sapiens BRCA1 gene 
(ensemble gene ID: ENSG00000012048) is shown in green color in the following:19 5′ CAT 
GAT TTT GAA GTC AGA GGA GAT GTG GTC AAT GGA AGA AAC CAC CAA GGT 
CCA AAG CGA GCA AGA GAA TCC C CAG GAC AGA AAG GTA AAG CTC CCT CCC 
TCA AGT TGA CAA AAA TCT CAC CCC ACC ACT CTG TAT TC 3′. While the specific 
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1 min (=6,500 x g)
1 min (=6,500 x g)
3 min (=12,000 x g)
1 min (=6,500 x g)
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4. Wash to Remove Contaminants
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Figure 4.6 Schematic of isolation of genomic DNA from a primary breast cancer cell line. 
(GenElute mammalian genomic DNA miniprep Kit (Sigma))   
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fragment sequence around exon 20 in the BRCA1 gene that was extracted from the nucleus of the 
primary breast cancer cell line (HCC1937, ATCC) has a single insertion C at position 5382 (in 
red color in italized font). For the PCR reaction, the extracted genomic DNA was used as the 
DNA template, in either a purified format or as was isolated from the cell line. The two primers 
for the PCR reaction were: 5'- AGG AGA TGT GGT CAA TGG AAG AAA -3' (upper primer, 
Tm = 56.2ºC) and 5'- GAA TAC AGA GTG GTG GGG TGA GAT -3' (lower primer, Tm = 
58.1ºC). Thus, the expected PCR product was a 121 bp DNA sequence: 5' A GGA GAT GTG 
GTC AAT GGA AGA AAC CAC CAA GGT CCA AAG CGA GCA AGA GAA TCC CCAG 
GAC AGA AAG GTA AAG CTC CCT CCC TCA AGT TGA CAA AAA TCT CAC CCC ACC 
ACT CTG TAT TC 3′. The PCR reaction included making a cocktail of all the necessary 
reagents at certain concentrations as is shown in Table 4.1, mixing thoroughly with a pipette tip, 








Table 4.1 A typical PCR cocktail used for the amplification of the BRCA1 gene sequence. 
 
PCR components Composition or Concentration (μM) Volume (μL) 
PCR buffer    10 
dNTPs 200 μM/dNTP 2 μL/dNTP 
Upper primer (24bp) 1 1 
Lower primer (24bp) 1 1 
PCR water   78 
DNA template Genomic DNA (HCC1937 cell line) 1 
DNA polymerase Taq DNA polymerase 1 
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All five vials were then placed into the metal block of the thermal cycler and a drop of mineral 
oil was added onto each cap of the five vials to protect the solution from evaporation during the 
heating process. Thermal cycling was achieved with a preset program based on parameters listed 










Fidelity of the PCR product was examined by analysis of the product with agarose gel 
electrophoresis (3%), followed by ethidium bromide (EtBr) staining and visualization with UV 
light at 254 nm. Optimization of the thermal cycling parameters was carried out by adjusting the 
annealing temperature and by using purified genomic DNA acquired through the solid-phase 
reverse immobilization (SPRI) technique. The integrity and purity of the PCR product was 
further improved by carrying out a secondary PCR reaction with a purified 1st PCR product as 
the DNA template. Purification of the 1st PCR product was accomplished with a purification kit 
called SpinPrep PCR clean-up kit (Novagen). This kit includes three major steps: binding, 
Table 4.2 The optimized thermal cycling parameters for PCR amplification of BRCA1 gene. 
     Name  Temperature Time  
First denaturing 94 ºC  5 min 
Denaturing 94 ºC  30 sec  
Annealing 63 ºC  40 sec 
Extension 72 ºC  40 sec  
Last extension 72 ºC  7 min 
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washing, and eluting, and it can be described briefly as the following: 17 μL of the PCR product 
was transferred to a clean 1.5-mL microcentrifuge tube, 68 μL of SpinPrep binding buffer was 
added and mixed well by agitation on a vortex mixer. The mixture was then transferred into a 
spin unit comprising a SpinPrep PCR filter inserted in a 2-mL receiver tube, and the assembly 
was then centrifuged at 12,000 rpm for 1 min. The filter unit was removed and inserted into 
another new 2-mL receiver tube, then 400 μL of the SpinPrep binding buffer was added, and the 
assembly was centrifuged at 12,000 rpm for 1 min. The filter unit was again removed and placed 
into another 2-mL receiver tube, then 500 μL of reconstituted SpinPrep washing buffer was 
added, and the assembly was centrifuged at 12,000 rpm for 1 min. The residual SpinPrep 
washing buffer was further removed by centrifuging the filter unit inserted in a new 2-mL 
receiver tube at 12,000 rpm for 2 min. The filter unit was finally transferred into a 1.5-mL 
elution receiver tube, into which was pipetted 50 μL of the prewarmed (70°C) SpinPrep elution 
buffer onto the filter membrane, the tube and its contents were incubated at room temperature for 
3 min, and then the PCR purified product was eluted by centrifugation for 1 min at 12,000 rpm.  
4.2.5  LDR FOR SINGLE-INSERTION DETECTION IN BRCA1 GENE 
 Since its invention in the early 1990s,12 the highly sensitive, specific, and accurate ligase 
detection reaction has been extensively applied to cancer disease diagnosis,15, 16, 20, 21 forensic 
testing13 and even coupled to immunoassays to make antigen detection ultrasensitive.22 Reported 
here is an example of the ligase detection reaction for sensitive single-mutation detection in the 
BRCA1 gene from a breast cancer cell line. The two primers designed for the ligation reaction 
were a modified version of the reported primer pair.16 The discriminating  primer: 5′-cgc aag gta 
ggt gct gta ccc gca-CAA AGC GAG CAA GAG AAT CCC-3′, in which the sequence in small 
letters was the complementary Zipcode sequence (cZip11),23 and the nucleotide cytosine at the 
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very end of 3′ was an insertion base. The common primer: 5′-P-CAG GAC AGA AAG GTA 
AAG CTC CCT C-Cy5.5-3′, in which there was a near-IR dye (Cy5.5) conjugated to the 3′ end 
and phosphate group at the 5′ end in order for the ligation to occur. The sequence of the expected 
LDR product is 5′-cgc aag gta ggt gct gta ccc gca-CAA AGC GAG CAA GAG AAT CCC 
CAG GAC AGA AAG GTA AAG CTC CCT C-Cy5.5-3′, which is a 70mer ss-DNA sequence 
with a cZip11 tag on one end (5′), with a near-IR dye on the other (3′).  
LDR is very much like PCR except that it is linearly amplified under a thermal stable 
DNA ligase. The commonly used LDR cocktail components are listed in Table 4.3, while the 
operating parameters are shown in Table 4.4 according to a typical standard ligase reaction.16 
Two negative control reactions were also carried out to test the specificity of the ligase reaction 
under the same operating parameters, except that there are slight and unique differences in terms 
of components of the LDR cocktail; one negative control used a different discriminating primer 
in which an insertion A instead of C was at the 3′ end, while another negative control consisted 









Table 4.3 Components of the LDR cocktails for the test sample and the two negative controls. 
LDR  Negative Control #1 Negative Control #2 
LDR buffer LDR buffer LDR buffer 
Nanopure water Nanopure water Nanopure water  
Discriminating Primer  
(w/ insertion C, 50 nM) 
Discriminating Primer 
(w/insertion A, 50 nM) 
Discriminating Primer 
(w/insertion C, 50 nM)  
Common Primer (50 nM) Common Primer (50 nM) Common Primer (50 nM) 
DNA template (1.25 nM, 
2nd PCR purified product) 
DNA template (1.25 nM, 
2nd PCR purified product)
DNA template (1.25 nM, 
gDNA from cell line HT29)







4.2.6 IMMOBILIZATION OF ZIPCODE11 OLIGO SEQUENCES ON UV-MODIFIED 
PMMA SURFACES 
Immobilization of oligo DNA sequences (Zipcode11: 5'-TGC GGG TAC AGC ACC 
TAC CTT GCG-(dT)15-(CH2)6-NH2-3') was tried in different buffer systems and coupled 












































































































































































































Scheme 4.1 Patterned immobilization of amine-terminated oligonucleotides on UV-
modified PMMA surfaces. 
Table 4.4 The typical operating parameters in the LDR reaction (40 cycles) used here. 
                  
2 min65 ºC Annealing
30 sec 94 ºC Denaturing
2 min94 ºC First denaturing
Time Temperature Name 
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The procedure can be briefly described as follows: precleaned pieces of PMMA sheet were 
exposed to UV light (see Chapter 2) through a contact photomask for 30 min, rinsed with IPA, 
and dried with house nitrogen. Zipcode11 oligo DNA was diluted with MES buffer to intended 
concentration, mixed with 40 mM EDC, and then immediately sandwiched between two pieces 
of UV-modified PMMA sheet. The sandwiched chips were incubated at 4°C overnight or at 
room temperature for 3 h, then rinsed with 2x SSPE buffer, followed by rinsing with nanopure 
water and gently drying with house nitrogen. Confirmation and optimization of the 
immobilization by using different buffer systems were monitored by X-ray Photoelectron 
Spectroscopy (XPS). 
4.2.7 HYBRIDIZATION OF LDR PRODUCTS TO IMMOBILIZED ZIPCODE11  
SEQUENCES 
As was illustrated in Figure 4.5, the LDR product sequence for the test sample that 
carries a complementary Zipcode sequence (cZipcode 11) at one end should hybridize to the 
immobilized Zipcode sequence (Zip11), and its presence can be detected by near-IR fluorescence 
detection. The hybridization conditions were totally dependent on the complementary Zipcode11 
sequence and independent of the other part in the LDR product sequence bases, which is why the 
name of universal Zipcode sequence is used. The protocol for the hybridization, signal detection 
and analysis was taken from previous reported work 24 and can be generally described as 
follows: the LDR product was diluted in 5x SSPE buffer to an intended concentration, 5 μL was 
spotted on the immobilized Zipcode11 area, and the LDR product/Zipcode 11-PMMA was 
incubated for 3h in a dark, humid container placed in a hybridization oven which had already 
been preheated and equilibrated at 50°C. After incubation, the surface was rinsed with 2x SSPE 
buffer, then placed in fresh 2x SSPE buffer, and the surface was thoroughly cleaned by shaking 
the PMMA sheet in the 2x SSPE buffer on an orbital shaker for at least 15 min twice. The chip 
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was at last gently dried with house nitrogen and then examined using a fluorescence scanning 
microscope. 
4.3  RESULTS AND DISCUSSION 
4.3.1  FIDELITY OF PCR PRODUCT AND OPTIMIZATION OF THE PCR 
REACTION 
Fidelity of PCR products is mostly determined by the design of the specific primers and 
choice of an optimum annealing temperature. In this work, both primers were chosen and 
optimized by a program which automatically checks the specificity of primer pairs to avoid any 
possible formation of self-dimers, hetero-dimers, and hairpins. Therefore, optimization of the 
PCR reaction was mainly carried out by optimizing the annealing temperature and pre-treatment 
of the genomic DNA template.  
Depicted in Figure 4.7 are agarose gel electrophoresis results of PCR products that were 
produced under different annealing temperatures. Lane 1 and 8 are 100bp DNA step ladder, 
Lanes 2 and 3 are PCR products produced under annealing temperature of 53°C, lanes 4 and 5 
are PCR products produced under annealing temperature of 59°C, and lanes 6 and 7 are PCR 
products produced under annealing temperature of 63°C. As is noticed from the gel image, there 
are least non-specific PCR products (products other than the expected 121bp PCR product) for 
annealing temperature of 63°C compared to the other two annealing temperatures.  
Lanes 3, 5 and 7 are PCR products with purified gDNA as the template while lanes 2, 4 
and 6 are PCR products using unpurified gDNA as the template. The gel image also disclosed a 
fact that purification of the gDNA with SPRI didn’t really help to produce more specific PCR 
product, but rather eliminated the PCR product completely (see Lanes 3, 5, and 7) although the 
mechanism behind this phenomenon is still not very clear yet. A possibility that can be drawn 
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from a preliminary analysis is that the magnetic beads used in SPRI purification probably 
















The intensity of the expected PCR product was not very strong, therefore a secondary 
PCR reaction was performed in order to prepare a PCR product of better quantity and specificity. 
The secondary PCR was carried out using 63°C as the annealing temperature; the purified 1st 
PCR product was used as the DNA template, and all other parameters were remained the same as 
that in the first PCR reaction. Shown in Figure 4.8 is a typical agarose gel electrophoresis image 
of the purified 2nd PCR product. 
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Figure 4.7 Agarose gel electrophoresis of PCR products obtained under different annealing 
temperatures. Lanes 1 and 8 are 100bp DNA step ladder; Lanes 2, 4, and 6 are PCR products 
using unpurified gDNA as the template; Lanes 3, 5 and 7 with purified gDNA as the 
template. Annealing temperatures are 53°C for lane 2 and 3, 59°C for lane 4 and 5, and 63°C 
















A bright band at 121bp was clearly shown. The quality of the secondary PCR product further 
determined the quality of the LDR reaction in which the secondary PCR product was used as the 
DNA template for the ligation. 
4.3.2  LDR PRODUCTS MONITORED BY DNA POLYACRYLAMIDE GEL 
ELECTROPHORESIS (PAGE) 
 Following PCR amplification of the region of interest, the mutation (single insertion C at 
5382 position in exon 20 of BRCA1 gene from the genomic DNA of HCC1937 breast cancer cell 
line) was detected in ligase detection reaction, in which a unique thermal stable ligase joined the 
pair of adjacent oligonucleotides complementary to the DNA sequence of interest (see Figure 
4.5). Ligation occurs only when the nucleotide at the junction between the paired 
                                           










Figure 4.8 Agarose gel electrophoresis of the 2nd PCR product. Lane 1 is a 25bp DNA step 
ladder, while Lane 3 is the secondary PCR product (121bp). There is no injection in Lane 2. 
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oligonucleotides is exactly complementary to that in the DNA template sequence of interest, 
therefore LDR is able to discriminate between wild-type and mutant sequences. Covalently 
attached on the 5' end of one of the paired oligonucleotides (paired primers) is a 24-mer non-
genomic oligonucleotide sequence that is complementary to a 24-mer Zipcode oligonucleotide 
sequence immobilized on a known location on the universal DNA array. On the 3' end of the 
same primer is the junction nucleotide that is perfectly complementary to that on the DNA 
sequence of interest. The 3' end of the other primer is labeled with a near-IR fluorescent dye 
(Cy5.5, λabs = 685 nm and λem = 706 nm) and the 5' end of the same primer is phosphorylated. 
Therefore, observation of fluorescence signal from the universal DNA array indicates the 
presence of the single-point mutation only when the ligation is successful.  
Fidelity of the LDR product was monitored by DNA poly(acrylamide) gel electrophoresis 
coupled to a near-IR fluorescence detector. Displayed in Figure 4.9 is a typical PAGE image of 
LDR products of the test sample and the control samples. As is detailed in section 4.2, the DNA 
sizing ladder (Lanes 1 and 5 in Figure 4.9) used in PAGE for LDR product analysis are DNA 
strands that are evenly conjugated to a 700-nm fluorescent dye, and the expected LDR product is 
also labeled with a near-IR dye on the 3' end of the sequence (see Figure 4.5). For control #1 
(lane 3 in Figure 4.9), there is an adenine nucleotide at the junction of the paired primers instead 
of a cytosine nucleotide; thus no ligation between the 3' end of the discriminating primer and the 
5' end of the common primer shall occur during LDR thermal cycling. Therefore no fluorescent 
DNA band at the 70mer shall be produced, and this is observed.  
For control #2 (Lane 4 in Figure 4.9), the DNA template used in the LDR is a wild-type 
instead of the mutated BRCA1 gene, thus the nucleotide at the junction of the adjacent paired 
primers is not complementary to that on the DNA sequence of the wild type, and no ligation shall 
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occur. This is borne out by the lack of fluorescence signal at the 70mer position on the PAGE 
image. It is clearly seen that there is a bright fluorescent band at the 70mer position for the tested 
LDR sample (Lane 2 in Figure 4.9), which indicates success of the ligation for the C-insertion 




















                                                    





                  
Figure 4.9 Poly(acrylamide) gel electrophoresis of the LDR products from the test sample and 
control samples. Lanes 1 and 5 are the DNA sizing standard (50-350bp, Licor), Lane 2 is the 
LDR product with the secondary PCR product as the DNA template, while Lanes 3 and 4 are 
the two negative controls. Lane 3 is the product using a discriminating primer with an 
insertion A instead of C in the specific position, and Lane 4 is the product using the DNA 
template isolated from a wild-type cell line. 
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4.3.3 XPS ANALYSIS OF IMMOBILIZED ZIPCODE11 OLIGONUCLEOTIDES ON  
UV MODIFIED PMMA SURFACES 
 As illustrated in reaction Scheme 4.1, immobilization of the amine-terminated Zipcode11 
oligo sequences will introduce nitrogen in the surface elemental composition of the modified 
PMMA compared to the pristine and UV-modified PMMA surfaces. XPS can be used to probe 
surface compositional changes and interrogate the surface density of the immobilized 
oligonucleotides.25 XPS analysis was carried out using the same protocol described in previous 
work (see Chapter 2).26, 27 In brief, the pristine, UV-modified, and oligonucleotide-immobilized 
PMMA chips were all thoroughly rinsed with nanopure water, dried with house nitrogen, and 
then placed in the sample transfer chamber (STC) and pumped down overnight. The samples 
were transferred to the sample analysis chamber (SAC) the next day when the vaccum pressure 
in the STC reached a minimum of 10-8 torr; survey and high-resolution spectra were acquired 
with the charge neutralizer turned on to compensate for possible charging effect on the insulating 
polymer. The peak at 397.3 eV signifies the existence of nitrogen (N1s emission), indicating the 
successful immobilization of amine-terminated Zipcode oligo sequences. Furthermore, the peak 
intensity can be used as a parameter to compare different immobilizations of oligonucleotides 
assuming that surface treatments prior to and after immobilization are the same for each type of 
immobilization.  
 Shown in Figure 4.10 are N1s high-resolution XPS spectra from the dumbbell-patterned, 
UV-modified PMMA surfaces, which includes both the UV-modified and the pristine PMMA 
areas, resulted from immobilization reactions using the same concentration of Zipcode11 
oligonucleotide (10 μM) and EDC (100 mM), the same buffer composition (PBS buffer), but 
under different buffer pH values. As is clearly demonstrated in Figure 4.10, the N1s signals from  
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Figure 4.10 XPS spectra of variously-treated PMMA surfaces treated with Zipcode11 
oligo sequences with the same buffer system but under different pH values on UV-
modified PMMA surfaces (top), and pristine PMMA surfaces (bottom); the latter was to 
test for non-specific adsorption of Zip11 on the pristine PMMA surfaces. 
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PMMA sheets, while dramatically different in the pristine PMMA area; there was significant 
non-specific adsorption resulting from the pH 11.49 PBS buffer system, while a negligible 
amount of non-specific adsorption was produced under pH 7.38 PBS buffer system. The reason 
for this non-specific adsorption is still under investigation. However, by a preliminary analysis, it 
is believed that buffers with different pH values infer different level of charges onto the DNA 
strands, therefore changing the net surface charges on the DNA strands. Hence the electrostatic 
interaction between the treated PMMA surface and the charged DNA strand is uniquely different 
under immobilization conditions.   
4.3.4 NEAR-IR LASER-INDUCED FLUORESCENCE SCANNING OF PMMA CHIPS  
RESULTING FROM HYBRIDIZATION REACTIONS 
  After rinsing with 2x SSPE buffer and gentle drying with house nitrogen, hybridization 
chips were immediately scanned with a home-built near-IR, laser-induced fluorescence scanner 
in a darkroom laboratory. Images were analyzed with a home-built program called HarpPlayer. 
As is demonstrated in Figure 4.11, there are bright fluorescence spots at locations where the 











Figure 4.11 Near-IR, laser-induced fluorescence scanning image of the hybridization event 
between the immobilized Zipcode11 and the LDR product of the test sample. 
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In the control experiments where the two control LDR samples were incubated with Zipcode11-
immobilized PMMA chips, there also appeared fluorescent signal which was attributed to the 











A primary breast cancer cell line was successfully cultured and is readily available for 
future applications. As one of the applications of the cultured cell line, BRCA1 mutated genomic 
materials were successfully prepared for future fabrication of hybrid biosensor systems. The 
detailed outcomes can be summarized and conclusions are drawn as follows. Genomic DNA 
from the cell line was successfully isolated and BRCA1 gene was investigated on the single-
insertion C-containing specific region of exon 20 through PCR/LDR combined assays. PCR was 
carried out and optimized to obtain the targeting sequence in exon 20 of BRCA1 gene, and 
proved to be in good quantity and quality as was evidenced by agarose gel electrophoresis 
results. The mutated genomic material was then obtained by LDR reaction using the DNA 
template sequence prepared by PCR. LDR products were analyzed by PAGE and were shown to 
      
    
     Figure 4.12 Near-IR, laser-induced fluorescence scanning images of the hybridization event    
      between the immobilized Zipcode11 and the LDR products of the two control samples. 
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have good integrity. Proof of concept of the array-based assay on the LDR test sample and the 
two negative controls showed self-consistent results: the hybridization of the LDR test sample 
was successful, but due to the interfering content of the excess fluorescent common primer in the 
LDR product, there was no significant discrimination between the test sample and the controls in 
terms of fluorescence intensity of the hybridization event; but the expected 70mer LDR product 
only appeared in the test sample and not the control samples on the PAGE gel image. Therefore, 
it is safe to conclude that the LDR product of the test sample was successfully prepared.  
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CHAPTER 5.  PREPARATION OF BREAST CANCER PROTEIN BIOMARKER 
TARGETING MATERIALS 
5.1 INTRODUCTION  
 As is true with most other cancer diseases, it is often futile and disfiguring to treat the 
cancer when it reaches its advanced stages. Therefore, it is crucial to develop techniques that are 
capable of detecting breast tumor formation accurately at its earliest stage and subsequently take 
appropriate measures for treatment.1  
Among the screening and testing methods, tumor markers are one of the targets used for 
early detection and diagnosis of cancers. Tumor markers are materials produced by tumors or by 
other cells of the body induced by cancer or certain noncancerous conditions. Usually, these 
materials may be found in the blood, urine, tumor, and other tissues. Genomic and proteomic-
based biomarkers are the most widely studied tumor markers for early detection of cancers; 
genomic biomarkers are the genetic mutations or alterations in specific genes, while proteomic 
biomarkers are the changes in protein shape, function, and pattern of expression due to cancerous 
conditions.  
Compared to genomic biomarkers, protein biomarkers are much more complicated due to 
the huge total number of proteins in the cell, variation of proteins among individuals, different 
cells, and even different developmental stages of the same cell type. Basically, proteomic 
biomarkers are very dynamic while genomic biomarkers are relatively static. Protein biomarkers 
have also been identified as important factors in diagnosing and monitoring cancer diseases. 
Changes in protein structure, expression patterns, and function may indicate predisposition to 
cancerous conditions, body response to drug treatment, and relapse of cancer diseases. Moreover, 
genetic biomarkers may, in some cases, not suffice to correctly identify a specific phenotype, 
especially in the early stages of tumor development due to the static nature of the cell’s genome.  
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Therefore, it is desirable to look at protein expression levels, because the proteome (entire 
complement of proteins expressed by a single cell, tissue, or organ) profile is highly dynamic 
(responds quickly to external stimuli); it is the proteins that comprise the proteome which 
regulate processes resulting in the phenotype. Specifically for breast cancer, protein biomarkers 
have proven to be valuable in diagnosis, prognosis, and monitoring of disease therapy. Strategies 
for early diagnosis of breast cancer or breast cancer predisposition are: screening for genetic 
mutations in genetic biomarkers especially for high-risk populations and examining proteomic 
biomarkers such as Her2/neu, CEA, MUC-1, and mammoglobin; and accurate and early staging 
of breast cancer diseases by analysis of micrometastasis of breast cancer. 
As it is known that there are genetic, proteomic, and metabolic biomarkers for a specific 
cancer disease, it is desirable to simultaneously assay all different types of biomarkers at the 
same platform in order to build a comprehensive diagnosis of the disease. There are a number of 
reported techniques for screening and examining each type of biomarker: 2-dimensional gel 
electrophoresis after isolation of the protein content from cells, mass spectrometry, and the 
newly developed biochip technologies. Simultaneous assaying of different types of biomarkers 
on the same platform is still at early stages. The concept of DNA-directed protein assay is to 
convert a DNA chip into a protein chip, thereby it is possible to assay both DNA and protein 
analytes on the same DNA-chip platform. Conjugation of a protein with an oligonucleotide is the 
first step to achieve this hybrid assay. There are several strategies for preparing protein-DNA 
conjugates. One is directly utilizing the cysteine residue on the protein and links the protein to a 
thiol-reactive oligonucleotide sequence.2, 3 However, there are very few free cysteines on 
secreted recombinant proteins such as antibodies, due to the oxidizing nature of the subcellular 
environment.4 The second strategy is to use bifunctional cross-linkers, either small molecule 
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such as sulfo-SMPB or biotin-streptavidin interaction,5-10 to covalently link the amino group or 
carboxylic acid group on the protein to a derivatized oligonucleotide. The disadvantage of using 
this strategy is that it is difficult to control the number and topology of the conjugation sites, 
hence resulting in heterogeneity of the conjugates. The third strategy is to create a peptide bond 
between a protein and an oligonucleotide via a process named “expressed protein ligation”,11, 12 
during which a fusion protein with  an intein moiety and a cellulose-binding domain (CBD) for 
purification is expressed, and then the protein is cleaved from the intein-CBD partner under 
reducing and low-temperature conditions, thereby generating a purified protein with a C-
terminus α-thioester bond. This bond can be linked directly to thiol-derivatized oligonucleotide 
sequences. The most drawback of this strategy is that it is time-consuming, often taking days for 
splicing the proteins and preparing the conjugates.  
Among the arena of researching protein-DNA conjugates are those by Niemeyer and 
coworkers who have invested significant efforts in developing and applying the concept of DNA 
directed protein assays since mid 1990s,13 in which biotin labeled antibody molecules are linked 
to biotin labeled ss-DNA molecules through a cross-linking molecule called streptavidin (STV) 
which has four biotin-binding domains. Then the antibody-DNA complex is hybridized to its 
complementary oligonucleic acid sequences arrayed on a DNA chip (see Figure 5.1). The assay 
outcome is transduced through color changes in the enzymatic reaction upon the formation of a 
traditional Enzyme Linked Immunosorbent Assay (ELISA) comprised of the capture antibody-
DNA complex, antigen, and the enzyme linked detection antibody. The main theme in the 
reported DNA-directed protein assays including those by Neimeyer and coworkers, though is to 
convert the DNA chip into a protein chip, thereby to analyze the targeting protein materials in a 
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much more economical way,7 especially when lower protein concentration and smaller array 
















 The DNA-directed protein assay allows economical analysis of protein targets, but in 
principle it also provides new ways of assaying both genomic and protein targeting materials 
simultaneously on the same platform. To fabricate such a platform, the first functional layer 
would be the specifically designed oligonucleotide sequences addressed in microarray spots 
which in concept are similar but in size much smaller than the microtiter plates used in 
Neimeyer’s work. Instead of only assaying protein materials using the DNA titer plate, in the 
 
 
Figure 5.1 Schematic diagram of the DNA directed assay.2 STV refers to streptavidin, a 
protein with four monomer domains. Biotin is a small organic molecule that recognizes the 
monomer domain in the streptavidin molecule. AP refers to alkaline phosphatase, an enzyme 
specifically for the oxidation of alkaline phosphate-containing molecules.   
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work reported here both genetic mutated materials and protein biomarker antigens—each 
incorporated with a specific oligonucleotide sequence that is complementary to one of those 
sequences in the microarray spots—are to be analyzed in a so-called hybrid assay format, 
through the base-pair hybridization reactions on the microfluidic platform. Signal generation and 
transduction are through the near-IR lased-induced fluorescence detection method because it is 
one of the most sensitive detection method so far reported. A simplified representation of the 
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Figure 5.2 Representation of the hybrid bioassay on a microfluidic platform. As a model 
system, the genetic mutational material is related to the BRCA1 gene single point mutation 
(see Chapter 4) while the protein targeting material used here is a breast cancer protein 
biomarker CEA. 
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As is illustrated in Figure 5.2, on the microfluidic platform, there are arrays of Zipcode oligo 
DNA sequences covalently immobilized on the polymeric substrate. Then a mixture of both the 
genetic and proteomic targeting materials will be introduced in the sample reservoir and flowed 
through the microchannels. Hybridization interaction between the Zipcode probes and the 
targeting materials will be read out dynamically or offline through fluorescence imaging 
methods. Preparation of the materials for the genetic targets have been discussed in Chapter 4; 
hence, in this chapter, preparation of the protein targets will be detailed spanning the semi-
synthetic process and qualitative analysis of the product at each reaction step with a variety of 
complementary techniques. 
5.2  MATERIALS AND METHODS 
5.2.1 GENERAL 
The ultimate goal of the materials preparation is to covalently link single-stranded DNA 
sequences (cZipcode1) with anti-breast cancer biomarker antibodies (IgG), and to use this 
complex as a capture-based probe of breast cancer protein biomarker (antigen) detection on a 
hybrid biosensor system using a microdevice platform. The ss-DNA sequence (thiol-cZipcode1, 
24 bases, 5'- /5ThioMC6-D/GCT GAG GTC GAT GCT GAG GTC GCA -3') was customer 
synthesized by Integrated DNA Technologies (IDT) with standard desalting treatment. Mouse 
anti-human carcinoembryonic (CEA) monoclonal antibodies (IgG molecules in PBS buffer) were 
purchased from Fitzgerald Industries International, Inc., and used with proper dilution and buffer 
system (phosphate buffered EDTA; PBE). The heterobifunctional link molecule, sulfo-SMPB 
(MW 458.38Da, spacer length of 11.6 angstroms), was a product of Pierce Biotechnology, Inc., 
received in solid powder, and used in appropriate buffer system. The D-Salt Dextran Desalting 
Columns (MWCO: 5,000Da) was ordered from Pierce Inc. and used according to the protocol 
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provided by the company. Cleland’s REDUCTACRYL Reagent,14 or the solid-phase reduction 
agent DTT, was obtained from EMD Biosciences, Inc., and used according to the instructions 
provided by the company. Millex-GV Filter (0.22 µm, PVDF, 4 mm, non-sterile) was ordered 
from Millipore Corporation and used according to instructions accompanying the product. 
Another type of desalting column called NAP-5 columns are prepacked minicolumns purchased 
from GE healthcare, and were used as instructed by the company. All the buffer systems, 
including phosphate-buffered saline (PBS, 20 mM KH2PO4, 150 mM NaCl, pH 7.38), 
phosphate-buffered EDTA (PBE, 2 mM EDTA in PBS), nanopure water (18.0 Ω.cm) were home 
prepared or produced and further purified with sterilized filter bottle units (membrane pore size: 
0.2 µm).  
The overall reaction scheme of the cross linking is illustrated in Scheme 5.1, in which the 
lysine residue on the IgG antibody molecule is first linked to the succinimidyl ester group on the 
heterobifunctional linker sulfo-SMPB by forming an amide bond. The modified IgG antibody 
molecule, sulfo-SMPB-IgG is now carrying a free maleimidyl functional moiety which is thiol 
reactive. The thiol-derivatized cZipcode1 oligonucleotide sequence is custom-synthesized 
product, and received in oxidized form. This sequence is first reduced with solid-phase DTT to 
release free thiol functional groups, and then the free thiol group on the cZipcode1 sequence is 
ready to link to the maleimide moiety on sulfo-SMPB-IgG, thus the IgG antibody is cross-linked 
to the cZipcode1 oligonucleotide sequence through the heterobifunctional linker sulfo-SMPB. 
The detailed activation reaction of the thiol-derivatized cZipcode oligonucleotide sequences is 
depicted in Scheme 5.2. The thiol-derivatized cZipcode1 oligonucleotide equences that carry the 
DMTO protecting group are reduced by the solid-phase DTT and as a result, the thiol-derivatized 
cZipcode1 oligonucleotide sequences are converted into two types of SH-terminated molecules: 
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one is the cZipcode1 oligonucleotide sequence now bearing the free reactive sulfur hydryl group, 
and another is the small protecting molecule. The reducing agent DTT undergoes ring formation 
during the reaction: the two free thiol groups on it are oxidized and form disulfide bond, a six-








































































5.2.2 MODIFICATION OF IgG MOLECULES WITH SULFO-SMPB AS MONITORED  
BY UV-VIS SPECTROMETRY 
IgG antibodies (1.5 mgmL-1 or 10 μM in PBS buffer) were first diluted with PBE buffer 
to an intended concentration of 3.8 μM. Sulfo-SMPB was brought to room temperature and then 
weighed into the diluted antibody solution in at least 50-times molar excess of the antibody. The 
reaction mixture was then incubated at 4°C for two hours. The mixture was brought to room 
temperature and desalted with a D-salt dextran desalting column which had already been washed 
and equilibrated with PBE buffer. Compositional analysis of the collections from the desalting 
column was monitored by scanning UV-Vis spectrometry in which the absorbance at 280 nm is 
referred to be the modified antibody component. Concentrations of the collected antibody 
aliquots were determined based on the standard antibody sample prepared with the received 
antibody reagent in the same PBE buffer.       
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Scheme 5.2 Reduction of thiol-derivatized cZipcode1 DNA sequences with solid-phase DTT. 
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5.2.3 REDUCTION OF THIOL-DERIVATIZED ss-DNA SEQUENCES WITH DTT  
AS MONITORED WITH UV-VIS SPECTROMETRY 
 The thiol-derivatized cZipcode1 oligo DNA sequences were first diluted in PBE buffer to 
an intended concentration of 5 μM in a microcentrifuge tube and mixed well with gentle 
agitation on a vortex mixer. DTT resin was weighed into tube containing the oligo solution in 
about 100-times weight excess of the oligo DNA. The mixture was placed on the vortex and 
agitated for about 15 min at room temperature and then filtered into another new microtube in 
which desalting was achieved so as to get rid of the small SH-terminated protecting group which 
resulted from the reduction reaction. In the desalting process, 500 μL of reduction product was 
applied to the pre-equilibrated NAP-5 column, and around 1.0 mL of desalted reduction product 
was collected and then analyzed with UV-Vis scanning spectrometry; the absorbance at 260 nm 
was monitored to determine the presence of the activated cZipcode1 oligo DNA sequences.     
5.2.4 CROSS-LINKING OF MODIFIED IgG ANTIBODIES WITH ACTIVATED  
cZIPCODE OLIGO DNA SEQUENCES 
 The isolated, activated cZipcode1 oligo DNA sequences were immediately added to the 
modified IgG antibody solutions in a 1:1 molar ratio and incubated at 4°C for about two hours. 
Longer incubation of the reaction mixture will not do any harm to the reaction, though. The final 
cross-linked product then underwent desalting, purification, concentration, or buffer exchange in 
order for respective analyses to confirm the formation and to characterize the structure of the 
conjugate. 
5.2.5 MONITORING THE INTERMEDIATES WITH UV-VIS SPECTROMETRY 
The sulfo-SMPB-modified IgG antibody was desalted in order to get rid of the excess  
sulfo-SMPB as well as the released NHS ester, and then was analyzed with a Cary50 scanning 
UV-Vis spectrometer. Data was collected with a scanning range of 400 cm-1 to 200 cm-1 and 
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collected at an interval of 2 cm-1 at medium survey rate. During the reduction of thiol-derivatized 
cZipcode1 oligo DNA sequences, the reduced oligo was also desalted and monitored by UV-Vis 
scanning spectrometry in the same mode.  
5.2.6 CHARACTERIZATION OF STARTING MATERIALS, INTERMEDIATE, AND  
FINAL PRODUCT WITH MALDI-TOF MASS SPECTROMETRY 
 Mass spectrometry has proven to be powerful in the analysis of both proteins and DNA 
molecules in that this technique is able to identify compositions by providing information on an 
intrinsic physical parameter, molecular weight of the analytes. Matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI) coupled with a time of flight (TOF) analyzer 
is a well-known mass spectrometric technique used for analysis of complex mixtures because 
this technique is tolerant of salt and other impurities thus sample preparations are relatively easy 
and straightforward. In the reported work here, MALDI-TOF was performed on a Bruker Reflex 
III (Bruker, Breman, Germany) mass spectrometer operated in linear, positive ion mode with a 
N2 laser. The laser power was used at the threshold level required to generate signal, and the 
accelerating voltage was set to 28 kV. The instrument was calibrated with protein/peptide 
standards bracketing the molecular weights of the protein samples (typically mixtures of 
apomyoglobin and bovine serum albumin using doubly charged, singly charged and dimmer 
peaks as appropriate). Samples were prepared in 0.1% TFA at a concentration of 50 pmol/μL. 
Sinapinic acid (SA) was used as the matrix for proteins after desalting treatment with a protein 
trap while the DNA samples were desalted with Ziptip (a 10 μL pipette tip with a bed of 
chromatography media fixed at the end; Millipore) and spotted with DNA matrix (a mixture of 
THAP and HPA) on the MALDI target. Allotments of 1 mL of matrix and 1 mL of sample were 
thoroughly mixed together; 0.5 mL of this was spotted on the target plate and allowed to dry 
before being sent into the instrument for analysis.  
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5.2.7 CHARACTERIZATION OF STARTING MATERIALS, INTERMEDIATE, AND  
FINAL PRODUCT WITH ANIONIC ION EXCHANGE CHROMATOGRAPHY 
 High-performance liquid chromatography (HPLC) is a commonly used analysis 
technique for purification of mixtures of biomolecules such as DNA and proteins. The key in 
acquiring nice separation profiles lies in several parameters, including appropriate choice of 
stationary phase, optimization of the mobile phase composition, and application of optimum 
pressure and buffer gradients. Described here is a specific type of liquid chromatography, 
namely anionic ion exchange chromatography, in which the column (DNAPac PA-100 column, 
Dionex) is packed with a pellicular anion-exchange resin comprised of a 13-μm-diameter 
nonporous polymeric substrate to which is bound quaternary amine-functionalized microbeads 
(100-nm, alkyl quaternary ammonium-functionalized latex beads, see Figure 5.3). This 
microporous structure will result in higher resolution due to the rapid mass transport 
characteristics associated with the resin. The buffer used in the separation is composed of two 
buffer systems: buffer A is 20 mM Tris-HCl with 0.3 M NaCl at pH6.30, and buffer B is 20 mM 
Tris-HCl with 1 M NaCl at pH6.30. The structure of the microscale resin15 used as the packing 
materials in the ion exchange column is depicted in Figure 5.3, and the buffer gradient in the 
time table is listed in the following table. 







Table 5.1 Time table for the buffer gradient. 
Time  Flow  %A %B %C %D 
5.00 1.000 0.0 100.0 0.0 0.0 
35.00 1.000 0.0 0.0 100.0 0.0 
40.00 1.000 0.0 0.0 100.0 0.0 
40.10 1.000 0.0 100.0 0.0 0.0 














5.2.8 THEORY OF MALDI-TOF MASS SPECTROMETRY 
Lasers have been used in ion sources to generate gas-phase ions from solid or liquid 
samples deposited on a sample surface since the mid 1970s.16 By controlling the laser power, 
thermal decomposition of fragile analytes can be avoided. Unfortunately, the maximum mass 
that could be analyzed prior to 1988 was only about 1000 Da, depending on the laser beam used, 
because higher laser intensities will destroy the sample. With the pioneering work by Tanaka and 
coworkers who introduced matrix into the sample, desorption/ionisation of high-mass molecules 
without inducing fragmentation was achieved.17 Hillenkamp and co-workers improved this 
matrix idea by using organic molecules instead of cobalt as the matrix, significantly increasing 
the sensitivity of the mass analysis.18, 19  




Figure 5.3 Structure of the microscale resin (13-μm in diameter)4 used as packing 
materials in the column of the anion exchange chromatography. The positive charged 
particle is referring to the quaternary amine-functionalized latex beads with a diameter of 
100 nm.  
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In the work, a Bruker Reflex III MALDI-TOF (Bruker, Breman, Germany) instrument 
was used for analysis of both antibodies and oligo DNA sequences. This instrument is able to 
offer low limit of detection (~10-15 mole) and high resolution (routinely >15000 FWHM for m/z 
1000), allowing accurate determination of the molar mass of testing samples. A typical layout of 












As is shown in Figure 5.4, the major components in MALDI-TOF MS are the ion source, mass 
analyzer, and detector. Laser light is used to generate gas-phase ions from the dried mixture of 
sample and matrix (1:1000 ratio by concentration) that is deposited on the stainless steel MALDI 
target. The generated ions are then accelerated by a chosen accelerating potential to an 
electromagnetic field in the TOF mass analyzer. Sample ions with different mass-to-charge ratio 
will be separated in the analyzer and reach the detector at different times, and thus a mass 
spectrum is recorded.  
M+ m+








Figure 5.4 Schematic of MALDI-TOF mass spectrometer. 
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5.2.9 THEORY OF ION EXCHANGE CHROMATOGRAPHY 
Ion exchange chromatography is based on the difference of overall charges to separate 
molecules. It can be used for purification of proteins, oligonucleotides, peptides, or other charged 
molecules. The analyte of interest must have a charge opposite to that of the functional group 
attached to the packing resin in the separation column in order to bind. Because this interaction is 
coulombic, binding must take place under low ionic strength conditions while elution is achieved 
by increasing the ionic strength to break up the ionic interaction. 
 Depicted in Figure 5.5 is the block diagram of ion exchange chromatography (upper) 
which includes four main components: a pump that is used to pump buffers in different 
gradients, autosampler that can be programmed to draw samples automatically, ion exchange 
columns that are packed with specific ion exchange materials, and detector that can sense and 
transduce signals from the separated species. There are different detectors to choose such as 
fluorescence and UV detector. Here used in the research work is the broad spectrum UV 
detector. Illustrated in Figure 5.5 (lower) is an anion exchange packing materials, microbeads 
modified with positively charges species, thus it is capable of exchanging anions from the mobile 
phase, thereby results in the separation of species bearing different net negative charges on the 
surfaces. 
5.3 RESULTS AND DISCUSSION 
5.3.1 UV-VIS SPECTROMETRY 
 UV-Vis spectrometry is a fast technique for compositional analysis of liquid samples; it 
is especially informative for samples with very characteristic absorbance profile, such as nucleic 
acids at 260 nm and proteins at 280 nm. Concentrations of the sample can also be estimated if a 
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very similar standard sample is used for comparison. In the reported work, UV-Vis absorbance 





































































































































































Figure 5.5 Upper: block diagram of HPLC setup; Lower: schematic of anion exchange 
chromatrography using positively charged microbeads as packing materials in the column. 
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either the SMPB-IgG or the reduced cZipcode1 oligo DNA sequences (refer Scheme 5.1 and 
5.2).    
The desalting column used to separate the excess sulfo-SMPB and the released NHS ester 
from the reaction product sulfo-SMPB-IgG (Scheme 5.1) is called a D-salt dextran desalting 
columns which has a cutoff molecular weight of 5,000Da. During the desalting, large molecules 
such as IgG antibodies will come out first, then small molecules such as the sulfo-SMPB and the 
released NHS ester. As is shown in Figure 5.4 where the UV-Vis spectra of all the collections 
from the desalting column were recorded spanning absorbance wavelength of 200 nm to 400 nm, 
there are two set of absorbance peaks: one is at 280 nm (traces of collections 5, 6, 7 and the 
standard antibody sample in Figure 5.4) which is attributed to the IgG molecules, another is at 
269 nm (traces of collection 8, 9 and 10) which probably resulted from the sulfo-SMPB and 
NHS ester. Concentrations of SMPB-IgG in collections 5, 6, and 7 were also estimated by 
comparing their absorbance intensities with that of the standard IgG antibody sample which was 
prepared in the same PBE buffer at a concentration of 1.25 μM. Then the SMPB-IgG with a 
known concentration was added to the reduced and desalted cZipcode1 oligo DNA sample which 
has the same concentration to link the IgG with the cZipcode1 sequence.  
             Desalting of the reduction product of the thiol-derivatized cZipcode1 oligo DNA was 
carried out with NAP5 columns (MWCO = 5,000Da). There were three collections for each 
desalting. Based on the instructions of use provided for the NAP5 column, the elution buffer 
came out into the first collection, the reduced cZipcode1 sequence came out into the second 
collection, and very small molecules such as the protecting group came out into the third 
collection. Demonstrated in Figure 5.7 are the UV-Vis spectra of all the collections of the 


























































Figure 5.6 UV-Vis spectra of all collections from the desalting of SMPB-IgG reaction 
products. The standard antibody (IgG antibody) prepared in PBE buffer was also analyzed 


















There is clearly an absorbance peak at 260 nm in elution 2 as expected; the concentration of the 
reduced cZipcode1 sequence was estimated by comparing its absorbance intensity with that of 
the standard cZipcode1 sample which was prepared in PBS buffer at a concentration of 2 μM. 
The cZipcode1 sequence with free sulfur hydryl groups can now readily react with the sulfo-
SMPB modified IgG antibodies. All the starting reagents, intermediate product, and the final 
cross-linking product were further confirmed and monitored by MALDI-TOF MS, a technique 
that is able to provide accurate mass determinations for each component in the samples.  


























Figure 5.7 UV-Vis spectra of elutions of the reduced thiol-cZipcode1 sequence, the 
standard cZipcode1 sample (2 μM), and PBS buffer. 
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5.3.2 MALDI-TOF MASS SPECTROMETRY 
 MALDI-TOF MS was used to test the integrity of all the starting materials including the 
thiol-derivatized cZipcode1 sequence and the mouse anti-human CEA monoclonal antibody 
(IgG). The major peak at 7776.5 m/z in the mass spectrum of Figure 5.6 indicated that the DNA 




















Figure 5.8 MALDI-TOF mass spectrum of the thiol-derivatized cZipcode1 oligo sequence. 
The oligo was first desalted with Ziptip, mixed with the DNA matrix (a mixture of THAP 


















There are three major peaks in the MALDI-TOF spectrum in Figure 5.9: one at an m/z of 149657 
attributed to the molecular ion of the IgG molecule, one at an m/z of 74777 representing the 
doubly charged molecular ion, and one at an m/z of 49934 representing the triply charged 
molecular ion of the IgG molecule. The spectrum confirms that the antibody is intact and of 
relatively high purity as a starting material. Intermediate products which include the sulfo-
SMPB-IgG and the reduced cZipcode1 sequence were also analyzed by MALDI-TOF to check if 
they were successfully prepared or not as can be seen in the spectra of Figure 5.8 and Figure 5.9. 
 



















Unfortunately, it is hard to conclude if the intermediate was the expected product or not, because 
the peak in the MALDI-TOF spectrum is very broad and the mass differences between the 
respective starting material and the resulting intermediate probably are too small to differentiate. 
The same situation was seen in both intermediate products; the sulfo-SMPB-IgG only has a mass 
difference of 241.3Da compared to the starting IgG molecule, while the reduced thiol-cZipcode1 
sequence only has a mass difference of 405Da compared to the thiol-derivatized cZipcode1 
sequence. 
 




















The final cross-linked product IgG-cZipcode1 complex was evaluated using the same 
mode of MALDI-TOF mass spectrometric analysis despite the non-conclusive result of the 
intermediate products. The mass spectrum in Figure 5.12 showed a small peak which has mass 
around 157553Da significantly higher than the starting materials. Interestingly, it is 
approximately the sum of the molecular weight of the IgG molecule and that of the reduced 
thiol-cZipcode1 sequence, implying that one oligo was attached to the IgG antibody molecule.   
 




















5.3.3 ANIONIC ION EXCHANGE CHROMATOGRAPHY 
Although all the intermediate reaction products were purified to some degree by desalting 
columns to get rid of small impurities, due to the fact that the MWCO of the desalting column 
used is 5,000Da, there would still is excess sulfo-SMPB-IgG or reduced thiol-cZipcode1 


















Figure 5.12 MALDI-TOF mass spectrum of the final cross-linking product IgG-cZipcode1. 
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product. HPLC has proven to be a powerful technique in separation of biomolecule mixtures. 
Thus, HPLC was explored to determine the best conditions for separation and purification of the 
final reaction product mixture.  
The separation conditions were modified as compared to those reported by Niemeyer et 
al., in which they tried to separate the conjugation product mixture that contains streptavidin, 
free IgG, and the streptavidin-modified IgG complex.13 The separation column used is an anionic 
exchange column that has quaternary charged ammonium ion present on the microsized latex 
beads which serve as the stationary phase. The Tris-HCl-NaCl gradient buffer system was the 
same as that used in Niemeyer’s work except that the pH value is adjusted according to the pI of 
the antibody used (mouse IgG1, from mouse ascites, pI = 6.4-7.6)20 to pH 9.0 instead of pH 6.3 
in the reference. Displayed in Figure 5.13 are the summarized elution profiles of all the starting 












Figure 5.13 Ion-exchange chromatographic elution profiles of starting reagents, 
intermediate, and the final cross-linked product with the cross-linking reaction buffer PBE 
as the sample carrying buffer. 
 166
The sample carrier buffer is PBE, while the running and elution buffers are each Tris-HCl 
buffer with a given concentration of NaCl. Absorbance of the UV light was used as the detection 
method. It is observed from Figure 5.13 that oligonucleotides eluted at 18 min, IgG and PBE 
both eluted at 1.2 min. It is probably because that EDTA in the PBE buffer was charged and 
interacted with the stationary phase during the separation. To confirm this assumption, all the 
samples were buffer-exchanged into PBS buffer, and ran HPLC with the same running method 
as that with PBE buffer as the sample carrier buffer. 
The elution profiles of all samples in PBS buffer, including starting reagents, 
















Figure 5.14 Ion-exchange chromatographic elution profiles of starting reagents, 
intermediate, and the final product with PBS as the sample carrying buffer. The inset small 
figures are the zoom-out profiles of the corresponding elution peak at elution time of 1.2 
min. 
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 It is noticed that there was no UV absorbance for the eluted control PBS buffer at elution 
time of 1.2 min. IgG molecules and its intermediate were still eluted at 1.2 min. Therefore, it 
confirmed the assumption of EDTA effect on the co-elution phenomenon in Figure 5.13. No 
peaks were seen in between the IgG molecule and the ss-DNA, as is expected of the final cross-
linked product. There are two possibilities: one is that the concentration of the final cross-linked 
product was too low to be detected, another is that the final cross-linked product might co-eluted 
with the starting IgG and the intermediate sulfo-SMPB-IgG molecules.      
5.4       CONCLUSIONS 
In summary, UV-Vis spectrometry was proved to be a straightforward technique for 
monitoring components of the intermediate product after desalting purification. It was verified 
by MALDI-TOF mass spectrometry that both starting reagents are of high purity and the final 
product was successfully prepared using the reaction scheme listed in Scheme 5.1 and 5.2. In 
order to get relatively pure final cross-linked product, ionic exchange chromatography was 
explored to ascertain the optimum conditions for separation and purification, and it was found 
that PBS buffer has to be the choice of carrying buffer instead of the cross-linking reaction buffer 
PBE because PBE co-eluted with IgG molecules. The pH value of the running buffer has to be 
adjusted according to pIs of the test samples, e.g. pH 9.0 is a better choice than pH 6.3 such that 
the IgG molecule may interact with the charged, microporous packing materials in the separation 
column (the microsized resins covered with the functionalized microbeads), hence the resolved 
elution of this molecule.    
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CHAPTER 6. SUMMARY OF CONCLUSIONS AND FUTURE WORK 
6.1 SUMMARY OF CONCLUSIONS 
 This research intended to explore a novel methodology in which breast cancer 
biomarkers among different classes are analyzed simultaneously on the same platform. It 
combined the hybrid biosensor system with polymer-based microfluidic devices; thus, by 
reaching this goal, it will provide a robust analytical diagnostic platform on which 
biomedically related events are analyzed in high throughput, high sensitivity, and high 
specificity, while at the same time will obtain low false positive and low false negative 
diagnostic results, therefore increasing the accuracy of the technique.   
 Background information on fields that are involved in the multiplexed 
microfluidic-based hybrid biosensor system is detailed in chapter 1. The overall research 
motivation, goal, and synopsis were first presented to give a big picture of this multi-
faceted project. It was followed by general information on cancer disease, especially that 
of breast cancer, spanning fundamental terms that will be frequently encountered in the 
following text, prevention, diagnosis, and general treatment techniques. The concept and 
importance of biomarkers were then introduced and followed by strategies of discovery 
and detection for both genetic and protein biomarkers in the format of single-analyte and 
multi-analyte assays. A brief literature review on the multianalyte assays was then 
presented. Background on the microfluidic device was an indispensable section because it 
was the platform of the hybrid biosensor system. Literature was also navigated on the 
idea of microfluidic-based multianalyte assays in a hybrid biosensor format; hence, the 
significance of the work was demonstrated. 
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In chapter 2, a simple and straightforward surface modification method, 
photochemistry method, on the microfluidid device substrate PMMA was reported. This 
surface modification produced roughly a monolayer of carboxylic functional groups, 
which made the surface amenable for further functionalization and applications. Changes 
on the surface properties induced by the photochemical modification were characterized 
in aspects of surface composition, surface topography, surface wettability, and effect on 
electroosmotic flows in the microchannels embossed in the PMMA substrate qualitatively 
and quantitatively. The surface modification mechanism was also explored in order to 
give an idea on controllable manipulation of surface properties for future 
implementations. A variety of analytical techniques were used for the characterization of 
the photochemical surface modification. Principles and instrumentation setup of these 
analytical tools were also described and illustrated in the chapter. Work presented in this 
chapter provided a new avenue for the spatially controllable surface modification of 
polymer-based BioMEMS devices which have attracted increased interest due to their 
intrinsic advantages, such as high-aspect-ratio, low cost of fabrication, and scalability.   
  In chapter 3, an effective antibody patterning method was investigated and 
characterized on both plain PMMA surfaces and PMMA microchannel surfaces. This 
method, using antibodies specific for a breast cancer biomarker carcinoembryonic 
antigen (CEA) as a model system, combines carbodiimide coupling chemistry with the 
direct, spatially-selective formation of carboxylic acid groups induced by exposure to UV 
light through a contact mask. Retention of the biochemical activity of the patterned, 
polymer-bound antibodies was confirmed, and surface ligand density measurements of 
immobilized antibodies yielded values characteristic of a submonolayer of antibody, with 
 172
the surface density being 80% larger for randomly immobilized antibodies in comparison 
to their protein-G oriented counterparts. Considering the fact that there is a large interest 
in developing disposable, polymer-based microdevices for potential applications in 
biomedical and clinical diagnosis of diseases that will require the use of immunological 
recognition agents in array-based formats, the work reported herein sheds some light on 
promising methods for the patterned immobilization of biologicals that are simple to 
utilize. 
  In chapter 4, a PCR/LDR combined assay was demonstrated in order to prepare 
breast cancer biomarker BRCA1 gene related mutational materials. The background 
information on BRCA1 gene as a breast cancer biomarker was introduced at the very 
beginning in order to emphasize the significance of study on this specific gene. Cell line 
used as the model study system for breast cancer was also validated in theory. 
Techniques, such as PCR, LDR, and slab gel electrophoresis that were heavily used in the 
experimental section, were thoroughly explained and displayed. In the following 
experimental sections, cell culture and isolation of genomic DNA were performed and 
succeeded. BRCA1 gene was investigated on the single insertion C-containing specific 
region of exon 20 through PCR/LDR combined assays. PCR reaction was also optimized 
to get the targeting sequence in good quantity and quality as was evidenced by agarose 
gel electrophoresis results. The targeted genomic mutational material was then achieved 
by LDR reaction on the DNA template sequence prepared by PCR. LDR products were 
analyzed on PAGE and shown to have good integrity.  
  Preparation of breast cancer protein biomarker targeting materials was detailed in 
chapter 5. First of all, the need of preparing protein biomarker targeting materials was 
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rationalized by briefing the value of applying multiple biomarkers from different classes 
in the diagnostic of breast cancer. Then, means of incorporating protein materials onto 
DNA-functionalized surfaces were explored in the literature, and a unique strategy was 
thus presented for the specific application in the work. Single-stranded DNA (cZipcode1) 
sequences were cross-linked through a heterobifunctional linker, sulfo-SMPB, to 
monoclonal antibodies that were raised against breast cancer biomarker CEA. A variety 
of analytical techniques were adopted to monitor the reaction and to characterize the 
product. The success of preparation of the final conjugation product, IgG-DNA, paved 
the way to fabrication of the hybrid biosensor system on which both the genetic 
mutational materials from BRCA1 gene and the protein targeting materials will be 
analyzed simultaneously through a universal DNA microarray format on the microfluidic 
platform.      
6.2 FUTURE WORK AND DIRECTIONS 
The goal of this research was to fabricate a hybrid biosensor system for multi-
analyte detection of breast cancer biomarkers on the multi-modular polymer-based 
microfluidic devices. Both genetic and protein targeting materials were successfully 
prepared, and the remaining issue is how to assay these materials, how to configure the 
hybrid biosensor format. Inspired by the mature technology soft lithography, the 
microfluidic device will be in a hybrid format, i.e., constructed in both thermal plastic 
PMMA and the soft material PDMS. The array of universal Zipcode DNA sequences will 
be produced by patterning lines of Zipcode DNA sequences with a PDMS stencil, and 
then, targeting materials will be flowed perpendicularly to the DNA lines. Arrays of 
















A PDMS stencil with four parallel channels will be fabricated using known 
techniques. Two types of Zipcode DNA sequences will be patterned covalently (see 
chapter 4) in parallel lines in quartets; therefore eight lines of DNA are to be 
immobilized. The two target materials, BRCA1 gene and CEA biomarkers incorporated in 
respective unique format, will be introduced to interact with each of these eight lines of 
DNA by another PDMS stencil that is aligned perpendicularly to the DNA lines. Thus, 
arrays of unique spots will be produced and ready for data analysis by fluorescence 
scanning imaging.   
UV Modified PMMA Surface




with Unique Zipcode Arrays
 
 
Figure 6.1 Schematic of patterning universal Zipcode DNA sequences through PDMS 
stencil on photochemically modified PMMA surfaces. 
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An alternative to this aforementioned patterning method is as follows. Arrays of 
Zipcode DNA sequences are first prepared by simply spotting each sequence onto the 
PMMA microchannels. The mixture of targeting materials is then flowed into each of the 
microchannels to interact with each of the DNA spot. 
A second phase for this project is to explore the effect of the orientation of the 
IgG antibodies on the IgG-DNA conjugate. In chapter 5, IgG antibodies were randomly 
linked to DNA through the amino groups on the lysine residues that are distributed 























Figure 6.2 Structure of IgG antibodies. 
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Thus, this strategy might not be able to reach the maximum binding capacity of 
the IgG antibodies. It is helpful to explore other functional sites on the IgG molecule, 
such as the carbohydrate moiety on the Fc of the IgG, disulfide bonds in the hinge region, 
and other possible receptors to avoid linking close to the two Ag binding regions.    
 The last phase of the research will be to test the feasibility of the hybrid biosensor 
system in the settings of breast cancer cells, on which surfaces the antigen protein 
biomarkers are bound and within which the genetic mutational materials related to the 
breast cancer are contained. 
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